Nephrology · CKD ComplicationsNephrology · Komplikasyon ng CKDNephrology · Komplikasyon sa CKDNephrology · Komplikasyun ning CKD

The Kidney–Brain Axis: Thinking, Memory, and Kidney DiseaseAng Ugnayan ng Bato at Utak: Pag-iisip, Memorya, at Sakit sa BatoAng Kalabotan sa Kidney ug Utok: Panghunahuna, Memorya, ug Sakit sa KidneyIng Ugnayan ning Batu at Utak: Pamanisip, Memorya, at Sakit king Batu

Why focus and memory can change with kidney disease and dialysis, when confusion is an emergency, what your team can check and treat, and what new research really shows.Bakit maaaring magbago ang focus at memorya sa sakit sa bato at dialysis, kailan emergency ang kalituhan, ano ang masusuri at magagamot ng team, at ano talaga ang ipinapakita ng bagong pananaliksik.Ngano nga mausab ang focus ug memorya sa sakit sa kidney ug dialysis, kanus-a emergency ang kalibog, unsay masusi ug matambalan sa team, ug unsay tinuod nga gipakita sa bag-ong panukiduki.Nanu ya at malyaring mibayu ing focus at memorya king sakit king batu at dialysis, kapilan emergency ing kalituan, nanu ing asuri at apanuluan ning team, at nanu talaga ing ipakit ning bayung pamanaliksik.

Summary

Burden. About 40% of adults with chronic kidney disease (CKD) screen positive for cognitive impairment, mainly executive and attention deficits; lower estimated glomerular filtration rate (eGFR) and albuminuria are associated with incident dementia.

Practice. Triage by tempo: acute change follows delirium and stroke pathways; gradual decline gets a collateral-informed assessment, medication review, and a validated screen timed consistently relative to hemodialysis (HD).

Evidence. No therapy has definitive randomized evidence for preventing or reversing CKD-associated decline; signals from intradialytic training and hemodiafiltration are secondary or patient-reported.

PublishedNailathalaGipatikPepalwal: ReferencesMga SanggunianMga TinubdanReng Reperensya: 45 Read timeOras ng pagbasaOras sa pagbasaOras ning pamamasa:
Semi-photorealistic 3D illustration of a human brain above a pair of kidneys on a soft pale-teal background, joined by a fine network of glowing small blood vessels that suggests the shared circulation linking the two organs.

Why kidney disease can change how you thinkBakit maaaring mabago ng sakit sa bato ang iyong pag-iisipNgano nga ang sakit sa kidney makausab sa imong panghunahunaNanu ya at ing sakit king batu malyari nang baguan ing pamanisip mu

Many people with chronic kidney disease (CKD) notice that it is harder to focus, follow several steps, or remember instructions. This is common, it is real, and it is not your fault. It often affects attention and planning more than memory. Some causes can be treated or eased, so new or worsening changes are worth raising with your kidney team. CKD also does not explain every thinking problem, which is why a proper check matters.Maraming may chronic kidney disease (CKD) ang nakakapansin na mas mahirap mag-focus, sumunod sa ilang hakbang, o tandaan ang mga bilin. Karaniwan ito, totoo ito, at hindi mo ito kasalanan. Mas madalas nitong naaapektuhan ang atensyon at pagpaplano kaysa sa memorya. May mga sanhing nagagamot o napapagaan, kaya sulit na sabihin sa iyong kidney team ang bago o lumalalang pagbabago. Hindi rin ipinapaliwanag ng CKD ang lahat ng problema sa pag-iisip, kaya mahalaga ang tamang pagsusuri.Daghang tawo nga adunay chronic kidney disease (CKD) ang makamatikod nga mas lisod na mag-focus, mosunod sa pipila ka lakang, o mahinumdom sa mga tambag. Kasagaran kini, tinuod kini, ug dili nimo kini sala. Mas kanunay nga maapektuhan ang atensyon ug pagplano kaysa sa memorya. Adunay mga hinungdan nga matambalan o mapagaan, busa angay isulti sa imong kidney team ang bag-o o nagkagrabe nga kausaban. Dili usab ipasabot sa CKD ang tanang problema sa panghunahuna, mao nga importante ang hustong pagsusi.Dakal a atin chronic kidney disease (CKD) ing makapansin a mas masakit ne ing mag-focus, tuki king pilan a hakbang, o tandanan ing bilin. Karaniwan ya ini, tutu ya, at ali me kasalanan. Mas maralas nang apektuan ing atensyon at pamagplanu kesa king memorya. Atin sanhing malyaring panuluan o pagaanan, kaya mayap nung sabian mu king kidney team mu ing bayu o lalalang pamagbayu. E na la rin ipaliwanag ning CKD ing sablang problema king pamanisip, kaya mayalaga ing tamang pamanyalidiri.

Your brain and your kidneys have something unusual in common. Both receive a very large share of the blood your heart pumps, and both depend on tiny, delicate blood vessels that work under steady pressure. When high blood pressure, diabetes, or smoking damage small blood vessels, they rarely damage them in one organ only. That is why protein leaking into the urine (albuminuria) is treated as a warning sign about blood vessels throughout the body, including the brain.May kakaibang pagkakapareho ang iyong utak at mga bato. Pareho silang tumatanggap ng napakalaking bahagi ng dugong ibinobomba ng puso, at pareho silang umaasa sa maliliit at maseselang ugat na gumagana sa tuloy-tuloy na presyon. Kapag sinira ng altapresyon, diabetes, o paninigarilyo ang maliliit na ugat, bihira na isang organ lamang ang tinatamaan. Kaya ang pagtagas ng protina sa ihi (albuminuria) ay itinuturing na babala tungkol sa mga ugat sa buong katawan, kasama ang utak.Adunay talagsaon nga pagkaparehas ang imong utok ug kidney. Pareho silang makadawat og dako kaayong bahin sa dugo nga gibomba sa kasingkasing, ug pareho silang nagsalig sa gagmay ug delikado nga ugat nga molihok sa padayon nga presyon. Kung madaot sa taas nga presyon, diabetes, o pagpanigarilyo ang gagmay nga ugat, talagsa ra nga usa ra ka organ ang maapektuhan. Mao nga ang pagtulo sa protina sa ihi (albuminuria) giisip nga pasidaan bahin sa mga ugat sa tibuok lawas, lakip ang utok.Atin kakaibang pamagkapareu ing utak at batu mu. Parehu lang tatanggap king makabaldug a bage ning daya a ibobomba ning pusu, at parehu lang aasa king malati at maselang ugat a gagana king tuloy-tuloy a presyon. Nung sirain ning altapresyon, diabetes, o panigarilyu ing malating ugat, bihira a metung mu a organ ing tatamaan. Kaya ing pamaglakwas ning protina king ini (albuminuria) ituring dang babala tungkul kareng ugat king sablang katawan, kayabe ne ing utak.

Kidney disease adds its own load on top. When the kidneys clear less, some waste products and medicines stay in the blood longer. Anemia, poor sleep, low mood, and the blood-pressure swings of dialysis can all make it harder to concentrate. Think of the brain as a busy office that needs clean water, steady electricity, and quiet. Kidney disease can disturb all three at once. The comparison has limits: the brain is not simply "poisoned", and for most people several smaller causes add up rather than one single cause.Nagdadagdag pa ng sariling pasanin ang sakit sa bato. Kapag mas kaunti ang nalilinis ng bato, mas matagal na nananatili sa dugo ang ilang dumi at gamot. Ang anemia, kulang na tulog, lungkot, at pag-uga ng presyon habang nagda-dialysis ay maaaring magpahirap sa pag-concentrate. Isipin ang utak na isang abalang opisina na kailangan ng malinis na tubig, tuloy-tuloy na kuryente, at katahimikan. Maaaring guluhin ng sakit sa bato ang tatlong ito nang sabay. May hangganan ang paghahambing: hindi basta "nalalason" ang utak, at sa karamihan, ilang maliliit na sanhi ang nagsasama-sama sa halip na iisang sanhi.Ang sakit sa kidney modugang pa og kaugalingong palas-anon. Kung mas gamay ang malimpyohan sa kidney, mas dugay magpabilin sa dugo ang pipila ka hugaw ug tambal. Ang anemia, kulang nga katulog, kaguol, ug pag-uyog sa presyon panahon sa dialysis makapalisod sa pag-concentrate. Hunahunaa ang utok nga usa ka busy nga opisina nga nanginahanglan og limpyo nga tubig, padayon nga kuryente, ug kahilom. Ang sakit sa kidney makagubot niining tulo dungan. Adunay utlanan ang pagtandi: dili lang basta "nahiloan" ang utok, ug sa kadaghanan, pipila ka gagmay nga hinungdan ang magtapok imbes nga usa ra.Mamagdagdag pa ing sakit king batu king sariling pasan. Nung mas kaunti ing malinis ning batu, mas matagal manatili king daya ing aliwang dinat at gamot. Ing anemia, kulang a tulug, lungkut, at pamag-uyug ning presyon kabang magda-dialysis malyari dang pasakitan ing pamag-concentrate. Isipan me ing utak a metung a abalang opisina a mangailangan malinis a danum, tuloy-tuloy a kuryente, at katahimikan. Malyari nang gulwan ning sakit king batu ing atlung ini kayabe. Atin anggang ing pamanyuring: e mu basta "melasun" ing utak, at king kalupan, pilan a malating sanhi ing mamagsama kesa metung mu.

Minimal line-art diagram of a kidney and a brain joined by dotted arrows labeled shared small blood vessels, retained waste, blood-pressure swings, and medicines, with a return arrow showing that thinking problems can make kidney care harder.

The kidney and the brain are linked through shared small blood vessels, waste the kidneys clear less well, blood-pressure swings during dialysis, and medicines. The return arrow is just as important: thinking problems can make it harder to manage medicines and appointments.Magkaugnay ang bato at utak sa pamamagitan ng magkaparehong maliliit na ugat, dumi na hindi gaanong nalilinis ng bato, pag-uga ng presyon habang nagda-dialysis, at mga gamot. Kasinghalaga ang pabalik na arrow: ang problema sa pag-iisip ay maaaring magpahirap sa pag-aalaga ng gamot at appointment.Ang kidney ug utok nagkadugtong pinaagi sa parehas nga gagmay nga ugat, hugaw nga dili kaayo malimpyohan sa kidney, pag-uyog sa presyon panahon sa dialysis, ug mga tambal. Parehas ka importante ang pabalik nga arrow: ang problema sa panghunahuna makapalisod sa pag-atiman sa tambal ug appointment.Magkaugnay ing batu at utak king parehung malating ugat, dinat a e masyadung malinis ning batu, pamag-uyug ning presyon kabang magda-dialysis, at gamot. Kasinghalaga ing pabalik a arrow: ing problema king pamanisip malyari nang pasakitan ing pamag-asikasu king gamot at appointment.

BP
Blood pressure

What thinking changes can look likeAno ang hitsura ng pagbabago sa pag-iisipUnsay hitsura sa kausaban sa panghunahunaNanu ing anyu ning pamagbayu king pamanisip

Doctors use the word cognition for all the ways the brain takes in, holds, and uses information. In kidney disease, the parts most often affected are attention (staying with a task), executive function (planning, organizing, switching between tasks), and processing speed (how quickly you take things in). Memory can be affected too. These are the skills people use to manage several medicines, a fluid allowance, and a dialysis schedule, so even mild changes can matter in daily life.Ginagamit ng mga doktor ang salitang cognition para sa lahat ng paraan ng utak sa pagtanggap, paghawak, at paggamit ng impormasyon. Sa sakit sa bato, kadalasang naaapektuhan ang atensyon (pananatili sa isang gawain), executive function (pagpaplano, pag-oorganisa, paglipat-lipat ng gawain), at bilis ng pagproseso (gaano kabilis mong naiintindihan ang mga bagay). Maaari ring maapektuhan ang memorya. Ito ang mga kakayahang ginagamit sa pag-aalaga ng ilang gamot, limitasyon sa tubig, at iskedyul ng dialysis, kaya kahit maliit na pagbabago ay mahalaga sa araw-araw.Gigamit sa mga doktor ang pulong cognition para sa tanang paagi sa utok sa pagdawat, paghupot, ug paggamit sa impormasyon. Sa sakit sa kidney, kasagarang maapektuhan ang atensyon (pagpabilin sa usa ka buluhaton), executive function (pagplano, pag-organisar, pagbalhin-balhin sa buluhaton), ug kapaspas sa pagproseso (unsa ka paspas nimo masabtan ang mga butang). Mahimo usab maapektuhan ang memorya. Kini ang mga abilidad nga gigamit sa pag-atiman sa pipila ka tambal, limitasyon sa tubig, ug iskedyul sa dialysis, busa bisan gamay nga kausaban importante sa adlaw-adlaw.Gamitan da ring doktor ing amanung cognition para king sablang paralan ning utak king pamanggap, pamaggawak, at pamamigamit impormasyun. King sakit king batu, maralas apektuan ing atensyon (pamanatili king metung a obra), executive function (pamagplanu, pamag-organisa, pamaglipat-lipat obra), at bilis ning pamagproseso (nung nanu kabilis mung maintindian deng bage). Malyari ring apektuan ing memorya. Ini la reng kakayanan a gamitan king pamag-asikasu pilan a gamot, limitasyun king danum, at iskedyul ning dialysis, kaya agyang malati a pamagbayu mayalaga king aldo-aldo.

Six illustrated everyday scenes of thinking changes in kidney disease: mixing up medicines, missing appointments, finding bills and forms harder, losing the thread of a conversation, feeling foggy after dialysis, and family noticing first.

Thinking changes in kidney disease usually show up in everyday tasks first: medicines, appointments, paperwork, conversations, and how you feel after dialysis. Family members often notice before you do.Kadalasang lumilitaw muna sa araw-araw na gawain ang pagbabago sa pag-iisip sa sakit sa bato: gamot, appointment, papeles, usapan, at pakiramdam pagkatapos ng dialysis. Madalas napapansin ito ng pamilya bago mo pa mapansin.Ang kausaban sa panghunahuna sa sakit sa kidney kasagaran makita una sa adlaw-adlaw nga buluhaton: tambal, appointment, papeles, istorya, ug pagbati human sa dialysis. Kasagaran mamatikdan kini sa pamilya una pa nimo.Ing pamagbayu king pamanisip king sakit king batu maralas lulutu muna kareng obra aldo-aldo: gamot, appointment, papeles, kuwentuan, at pamakiramdam kaibat ning dialysis. Maralas apansinan ne ning pamilya bayu mu pa mapansin.

Timeline in three colored bands: minutes to hours means an emergency and calling 911; hours to days or confusion that comes and goes means seeing a doctor today; weeks to months means telling your kidney team at the next visit.

How fast a change happened tells you how fast to act. Sudden change is an emergency; change over days needs a same-day check; slow change over months should be raised at your next visit.Kung gaano kabilis nangyari ang pagbabago, ganoon din kabilis dapat kumilos. Emergency ang biglaang pagbabago; kailangan ng pagsusuri sa parehong araw ang pagbabago sa loob ng ilang araw; sabihin sa susunod na konsulta ang dahan-dahang pagbabago sa loob ng ilang buwan.Kung unsa ka paspas nahitabo ang kausaban, mao usab ka paspas ang paglihok. Emergency ang kalit nga kausaban; kinahanglan og pagsusi sa samang adlaw ang kausaban sulod sa pipila ka adlaw; isulti sa sunod nga konsulta ang hinay-hinay nga kausaban sulod sa pipila ka bulan.Nung nanu kabilis mayari ing pamagbayu, antimo ya mu rin kabilis ing pamagkilus. Emergency ing biglang pamagbayu; kailangan pamanyalidiri king pareung aldo ing pamagbayu king pilan a aldo; sabian me king susunod a konsulta ing dahan-dahang pamagbayu king pilan a bulan.

How fast it changedGaano kabilis nagbagoUnsa ka paspas nausabNung nanu kabilis mibayuWhat it may meanAno ang maaaring ibig sabihinUnsay mahimong ipasabotNanu ing malyaring buri nang sabianWhat to doAno ang gagawinUnsay buhatonNanu ing gawan
Minutes to hours, or with a drooping face, weak arm, slurred speech, seizure, or hard to wakeIlang minuto hanggang oras, o may nakalaylay na mukha, mahinang braso, bulol na pananalita, kombulsyon, o mahirap gisinginPipila ka minuto hangtod oras, o adunay nahuyhoy nga nawong, huyang nga bukton, bulol nga pagsulti, kombulsyon, o lisod pukawonPilan a minutu angga king oras, o atin melaylay a lupa, malambut a gamat, bulol a pamanyalita, kombulsyon, o masakit pukawanStroke, a seizure, very low blood sugar, severe infection, or another emergencyStroke, kombulsyon, napakababang asukal, malubhang impeksyon, o iba pang emergencyStroke, kombulsyon, ubos kaayo nga asukal, grabe nga impeksyon, o laing emergencyStroke, kombulsyon, mabababa a asukal, malalang impeksyon, o aliwang emergencyEmergency now. Call 911 or go to the nearest emergency roomEmergency ngayon. Tumawag sa 911 o pumunta sa pinakamalapit na emergency roomEmergency karon. Tawag sa 911 o adto sa pinakaduol nga emergency roomEmergency ngeni. Tumawag king 911 o munta king pekamalapit a emergency room
Hours to days, or confusion that comes and goesIlang oras hanggang araw, o kalituhan na dumarating at nawawalaPipila ka oras hangtod adlaw, o kalibog nga moabot ug mawalaPilan a oras angga king aldo, o kalituan a dadatang at mawawalaDelirium from infection, a new medicine, dehydration, salt or sugar problems, or kidney failure getting worseDelirium dahil sa impeksyon, bagong gamot, dehydration, problema sa asin o asukal, o paglala ng kidney failureDelirium tungod sa impeksyon, bag-ong tambal, dehydration, problema sa asin o asukal, o paggrabe sa kidney failureDelirium uli ning impeksyon, bayung gamot, dehydration, problema king asin o asukal, o pamaglala ning kidney failureSame-day medical review. Call your doctor or go to the hospitalPagsusuri sa parehong araw. Tawagan ang doktor o pumunta sa ospitalPagsusi sa samang adlaw. Tawag sa doktor o adto sa ospitalPamanyalidiri king pareung aldo. Tawagan me ing doktor o munta king ospital
Weeks to months, slowlyIlang linggo hanggang buwan, dahan-dahanPipila ka semana hangtod bulan, hinay-hinayPilan a dominggu angga king bulan, dahan-dahanCKD-related changes, medicines, sleep, mood, hearing, anemia, or another brain conditionPagbabagong kaugnay ng CKD, gamot, tulog, lungkot, pandinig, anemia, o ibang kondisyon sa utakKausaban nga may kalabotan sa CKD, tambal, katulog, kaguol, pandungog, anemia, o laing kondisyon sa utokPamagbayu a kaugnay ning CKD, gamot, tulug, lungkut, pamakiramdam, anemia, o aliwang kondisyun king utakRaise it at your next visit, or sooner if daily tasks are slippingSabihin sa susunod na konsulta, o mas maaga kung napapabayaan na ang araw-araw na gawainIsulti sa sunod nga konsulta, o mas sayo kung napasagdan na ang adlaw-adlaw nga buluhatonSabian me king susunod a konsulta, o mas agad nung mapapabayan no reng obra aldo-aldo

You are not aloneHindi ka nag-iisaDili ka nag-inusaraAli ka bukud

When researchers combined 50 studies of about 25,000 people with CKD, roughly 4 in every 10 had some thinking problem on testing. The share was about 1 in 3 before dialysis, about 1 in 2 on hemodialysis (HD), almost 2 in 5 on peritoneal dialysis (PD), and about 1 in 4 after a kidney transplant. These numbers come from different tests used in different countries, so treat them as a rough picture. They describe groups of people, not your personal chance, and they do not mean that one kind of dialysis causes the difference: people who start each treatment are often different in age and health to begin with.Nang pagsamahin ng mga mananaliksik ang 50 pag-aaral sa humigit-kumulang 25,000 taong may CKD, mga 4 sa bawat 10 ang may problema sa pag-iisip sa pagsusuri. Mga 1 sa 3 bago mag-dialysis, mga 1 sa 2 sa hemodialysis (HD), halos 2 sa 5 sa peritoneal dialysis (PD), at mga 1 sa 4 pagkatapos ng kidney transplant. Galing ang mga numerong ito sa iba-ibang test sa iba-ibang bansa, kaya ituring itong magaspang na larawan. Inilalarawan nito ang grupo ng tao, hindi ang iyong personal na tsansa, at hindi ito nangangahulugang ang isang uri ng dialysis ang sanhi ng pagkakaiba: kadalasan ay magkaiba na sa edad at kalusugan ang mga nagsisimula sa bawat gamutan.Sa dihang gihiusa sa mga tigdukiduki ang 50 ka pagtuon sa mga 25,000 ka tawo nga adunay CKD, mga 4 sa matag 10 ang adunay problema sa panghunahuna sa pagsulay. Mga 1 sa 3 sa wala pa mag-dialysis, mga 1 sa 2 sa hemodialysis (HD), hapit 2 sa 5 sa peritoneal dialysis (PD), ug mga 1 sa 4 human sa kidney transplant. Gikan kini nga mga numero sa lain-laing pagsulay sa lain-laing nasud, busa isipa kini nga baga nga hulagway. Naghulagway kini sa grupo sa mga tawo, dili sa imong personal nga tsansa, ug wala kini nagpasabot nga usa ka matang sa dialysis ang hinungdan sa kalainan: kasagaran lahi na sa edad ug panglawas ang mosugod sa matag pagtambal.Kanita pamagsamanan da ring mananaliksik ing 50 a pamag-aral king lagyu 25,000 a tau a atin CKD, malapit 4 king balang 10 ing atin problema king pamanisip king pamanyalidiri. Malapit 1 king 3 bayu mag-dialysis, malapit 1 king 2 king hemodialysis (HD), malapit 2 king 5 king peritoneal dialysis (PD), at malapit 1 king 4 kaibat ning kidney transplant. Galing la reng numeru a reni king aliwa-aliwang test king aliwa-aliwang bansa, kaya ituring mu yang magaspang a larawan. Ilarawan na ning grupu da reng tau, e ing personal mung tsansa, at e na buring sabian a metung a klasi ning dialysis ing sanhi ning pamagkaiba: maralas aliwa na king edad at kalusugan deng mamagumpisa king balang panulu.

Icon array: about 1 in 3 people with kidney disease before dialysis, about 1 in 2 on hemodialysis, about 2 in 5 on peritoneal dialysis, and about 1 in 4 after a kidney transplant had some thinking problems on testing.

Across 50 studies, thinking problems on testing were common at every stage of kidney disease. These are rough group averages; they do not predict what will happen to you, and they do not show that one kind of dialysis causes more problems.Sa 50 pag-aaral, karaniwan ang problema sa pag-iisip sa pagsusuri sa bawat yugto ng sakit sa bato. Magaspang na karaniwan ito ng grupo; hindi nito hinuhulaan ang mangyayari sa iyo, at hindi nito ipinapakitang ang isang uri ng dialysis ang nagdudulot ng mas maraming problema.Sa 50 ka pagtuon, kasagaran ang problema sa panghunahuna sa pagsulay sa matag yugto sa sakit sa kidney. Baga nga kasagaran kini sa grupo; dili kini motagna kung unsay mahitabo kanimo, ug dili kini nagpakita nga usa ka matang sa dialysis ang hinungdan sa mas daghang problema.King 50 a pamag-aral, karaniwan ing problema king pamanisip king pamanyalidiri king balang yugtu ning sakit king batu. Magaspang a karaniwan ning grupu ini; e na uulan ing malyaring mayari keka, at e na ipakit a metung a klasi ning dialysis ing sanhi ning mas dakal a problema.

Large long-term studies also found that people with lower kidney function or more protein in the urine were more likely to be diagnosed with dementia years later. This is a link seen in populations, not proof that kidney disease alone causes dementia, and it cannot tell you what will happen to you. It is one more reason to protect both your kidneys and your blood vessels.Natuklasan din ng malalaking pangmatagalang pag-aaral na ang mga taong mas mababa ang gana ng bato o mas maraming protina sa ihi ay mas malamang na ma-diagnose ng dementia makalipas ang ilang taon. Ugnayang nakita ito sa populasyon, hindi patunay na ang sakit sa bato lamang ang nagdudulot ng dementia, at hindi nito masasabi kung ano ang mangyayari sa iyo. Isa pa itong dahilan para protektahan ang iyong bato at mga ugat.Nakaplagan usab sa dagkong dugay nga pagtuon nga ang mga tawo nga mas ubos ang gana sa kidney o mas daghang protina sa ihi mas lagmit nga ma-diagnose og dementia human sa pipila ka tuig. Kalabotan kini nga nakita sa populasyon, dili pamatuod nga ang sakit sa kidney ra ang hinungdan sa dementia, ug dili kini makasulti kung unsay mahitabo kanimo. Usa pa kini ka rason aron panalipdan ang imong kidney ug mga ugat.Atin la rin akit deng maragul a matagal a pamag-aral a deng tau a mas mababa ing gana ning batu o mas dakal a protina king ini mas malyari dang ma-diagnose dementia kaibat ning pilan a banwa. Ugnayan ya ini a akit king populasyun, e patunay a ing sakit king batu mu ing sanhi ning dementia, at e na asabi nung nanu ing malyari keka. Metung ya pang dahilan ini bang protektan me ing batu at ugat mu.

Four overlapping causesApat na magkakapatong na sanhiUpat ka nagsapaw nga hinungdanApat a mamagkapatung a sanhi

Scientists describe several pathways. In any one person, more than one is usually at work, and some are better proven than others.Inilalarawan ng mga siyentipiko ang ilang daanan. Sa isang tao, kadalasang higit sa isa ang gumagana, at may mas napatunayan kaysa sa iba.Gihulagway sa mga siyentista ang pipila ka agianan. Sa usa ka tawo, kasagaran labaw sa usa ang naglihok, ug ang uban mas napamatud-an kaysa sa uban.Ilarawan da ring siyentipiko ing pilan a dalanan. King metung a tau, maralas maigit king metung ing gagana, at atin mas mepatunayan kesa kareng aliwa.

CauseSanhiHinungdanSanhiWhat happensAno ang nangyayariUnsay mahitaboNanu ing mayayariHow sure we areGaano tayo kasiguradoUnsa kita kasiguradoNung nanu tayu kasiguradu
Shared blood-vessel damageMagkaparehong pinsala sa ugatParehas nga kadaot sa ugatParehung pinsala king ugatHigh blood pressure and diabetes injure the small vessels of both organs. Small areas of brain injury can slow thinking and planning.Sinisira ng altapresyon at diabetes ang maliliit na ugat ng dalawang organ. Ang maliliit na pinsala sa utak ay maaaring magpabagal ng pag-iisip at pagpaplano.Ang taas nga presyon ug diabetes makadaot sa gagmay nga ugat sa duha ka organ. Ang gagmay nga kadaot sa utok makapahinay sa panghunahuna ug pagplano.Sisirain ning altapresyon at diabetes ing malating ugat ning adwang organ. Ing malating pinsala king utak malyari nang pabagalan ing pamanisip at pamagplanu.Strong evidence from large human studiesMalakas na ebidensya mula sa malalaking pag-aaral sa taoLig-on nga ebidensya gikan sa dagkong pagtuon sa tawoMakapangyarian a ebidensya manibat king maragul a pamag-aral king tau
Waste the kidneys clear less wellDumi na hindi gaanong nalilinis ng batoHugaw nga dili kaayo malimpyohan sa kidneyDinat a e masyadung malinis ning batuSome wastes, partly made by gut bacteria, build up and stick to blood proteins, so standard dialysis removes them poorly. In the laboratory they irritate blood vessels and brain cells.Naiipon ang ilang dumi, na bahagyang gawa ng bacteria sa bituka, at kumakapit sa protina sa dugo, kaya hindi ito gaanong natatanggal ng karaniwang dialysis. Sa laboratoryo, iniirita nila ang ugat at selula ng utak.Ang pipila ka hugaw, nga bahin gihimo sa bacteria sa tinai, motapok ug mopilit sa protina sa dugo, busa dili kaayo kini makuha sa kasagarang dialysis. Sa laboratoryo, makairita kini sa ugat ug selula sa utok.Mipun la ring aliwang dinat, a bage gewa da ring bacteria king bituka, at kapit la king protina king daya, kaya e la masyadung makwa ning karaniwang dialysis. King laboratoryu, iirita da ring ugat at selula ning utak.Seen in laboratory work and linked in people; not yet proven to cause thinking problems in peopleNakita sa laboratoryo at may kaugnayan sa tao; hindi pa napapatunayang sanhi ng problema sa pag-iisip sa taoNakita sa laboratoryo ug may kalabotan sa tawo; wala pa napamatud-an nga hinungdan sa problema sa panghunahuna sa tawoAkit king laboratoryu at atin kaugnayan king tau; e pa mepatunayan a sanhi ning problema king pamanisip king tau
Blood-pressure swings during dialysisPag-uga ng presyon habang nagda-dialysisPag-uyog sa presyon panahon sa dialysisPamag-uyug ning presyon kabang magda-dialysisRemoving fluid quickly can lower blood flow to the brain for a while. In one study, brain oxygen dipped in about 1 of every 4 sessions, often when the blood pressure reading looked acceptable.Ang mabilis na pag-alis ng tubig ay maaaring pansamantalang magpababa ng daloy ng dugo sa utak. Sa isang pag-aaral, bumaba ang oxygen sa utak sa mga 1 sa bawat 4 na session, madalas kahit maayos ang nabasang presyon.Ang paspas nga pagkuha sa tubig makapaubos sa agos sa dugo ngadto sa utok sa makadiyot. Sa usa ka pagtuon, mius-os ang oxygen sa utok sa mga 1 sa matag 4 ka session, kasagaran bisan maayo ang nabasa nga presyon.Ing mabilis a pamaglako danum malyari nang pababan pansamantala ing dalan ning daya king utak. King metung a pamag-aral, mibaba ing oxygen king utak king malapit 1 king balang 4 a session, maralas agyang mayap ing abasang presyon.Measured directly during dialysis; long-term effect on thinking still being studiedDirektang nasukat habang nagda-dialysis; pinag-aaralan pa ang pangmatagalang epekto sa pag-iisipDirektang nasukod panahon sa dialysis; gitun-an pa ang dugay nga epekto sa panghunahunaDirektang asukat kabang magda-dialysis; pag-aralan pa ing matagal a epektu king pamanisip
Body-wide strain and medicinesPasanin ng buong katawan at mga gamotKabug-at sa tibuok lawas ug mga tambalPasan ning sablang katawan at gamotAnemia, inflammation, poor sleep, low mood, salt or sugar imbalance, and medicines that stay in the body longer when the kidneys are weak.Anemia, pamamaga, kulang na tulog, lungkot, hindi balanseng asin o asukal, at mga gamot na mas tumatagal sa katawan kapag mahina ang bato.Anemia, panghubag, kulang nga katulog, kaguol, dili balanse nga asin o asukal, ug mga tambal nga mas dugay magpabilin sa lawas kung huyang ang kidney.Anemia, pamamaga, kulang a tulug, lungkut, e balanseng asin o asukal, at gamot a mas matagal manatili king katawan nung malambut ing batu.Varies by person; several are treatable once foundNag-iiba sa bawat tao; ilan ang nagagamot kapag natagpuanLahi-lahi sa matag tawo; pipila ang matambalan kung makit-anAliwa-aliwa king balang tau; pilan ing malyaring panuluan nung akit
Review-style mechanism figure: a kidney and brain at organ level with magnified panels showing small-vessel injury, protein-bound uremic toxins from the gut crossing a leaky blood-brain barrier, falling cerebral blood flow during dialysis fluid removal, and medicines accumulating, ending in a summary flow from contributors to assessment to targeted care.

Four overlapping pathways link kidney disease and thinking problems. Solid arrows show links seen in people; dashed arrows show mechanisms still being tested.Apat na magkakapatong na daanan ang nag-uugnay sa sakit sa bato at problema sa pag-iisip. Ang buong arrow ay ugnayang nakita sa tao; ang putol-putol na arrow ay mekanismong sinusubok pa.Upat ka nagsapaw nga agianan ang nagdugtong sa sakit sa kidney ug problema sa panghunahuna. Ang tibuok nga arrow mao ang kalabotan nga nakita sa tawo; ang putol-putol nga arrow mao ang mekanismo nga gisulayan pa.Apat a mamagkapatung a dalanan ing mamag-ugnay king sakit king batu at problema king pamanisip. Ing buung arrow ugnayan a akit king tau; ing putul-putul a arrow mekanismu a subukan pa.

BBB
Blood–brain barrier
IS
Indoxyl sulfate
PCS
p-Cresyl sulfate
HD
Hemodialysis

Notice the timing, and tell the teamPansinin ang oras, at sabihin sa teamMatikdi ang oras, ug isulti sa teamPansinan me ing oras, at sabian mu king team

Many people on hemodialysis feel foggy or very tired for some hours after a session. That is worth reporting, because the team can look at how much fluid is being removed, how fast, and how your blood pressure behaves during treatment. Write down when the fogginess happens: before, during, or after dialysis, and how long it lasts. The pattern helps the team decide what to change.Maraming nagda-hemodialysis ang nakakaramdam ng malabong isip o sobrang pagod ilang oras pagkatapos ng session. Mahalagang i-report ito, dahil masusuri ng team kung gaano karaming tubig ang tinatanggal, gaano kabilis, at paano kumikilos ang iyong presyon habang ginagamot. Isulat kailan nangyayari ang pagkalabo: bago, habang, o pagkatapos ng dialysis, at gaano katagal. Tutulungan ng pattern ang team na magpasya kung ano ang babaguhin.Daghang nagda-hemodialysis ang mobati og hanap nga hunahuna o sobra nga kakapoy sulod sa pipila ka oras human sa session. Angay kini i-report, kay masusi sa team kung pila ka tubig ang gikuha, unsa ka paspas, ug unsaon paglihok sa imong presyon panahon sa pagtambal. Isulat kanus-a mahitabo ang pagkahanap: sa wala pa, samtang, o human sa dialysis, ug unsa kadugay. Ang pattern motabang sa team sa pagdesisyon kung unsay usbon.Dakal a magda-hemodialysis ing makaramdam malabung isip o sobrang kapagal pilan a oras kaibat ning session. Mayalaga ing i-report ya ini, uling asuri ning team nung pilan a danum ing makwa, nung nanu kabilis, at nung kapilan kikilos ing presyon mu kabang panulu. Isulat me nanu oras mayayari ing pamagkalabu: bayu, kabang, o kaibat ning dialysis, at nung nanu katagal. Tulungan ning pattern ing team bang magpasiya nung nanu ing bayuan.

Three-panel checklist for a dialysis day: before dialysis, during dialysis, and after dialysis, each with simple questions about fogginess, dizziness, sleep, and tiredness, ending with a reminder to bring the notes to the kidney team.

Noting when fogginess happens — before, during, or after dialysis — helps your team decide whether fluid removal, session length, sleep, or medicines are part of the cause.Ang pagtatala kung kailan nangyayari ang pagkalabo ng isip — bago, habang, o pagkatapos ng dialysis — ay tumutulong sa team na malaman kung bahagi ng sanhi ang pag-alis ng tubig, haba ng session, tulog, o gamot.Ang pagsulat kung kanus-a mahitabo ang pagkahanap sa hunahuna — sa wala pa, samtang, o human sa dialysis — motabang sa team nga mahibal-an kung bahin sa hinungdan ang pagkuha sa tubig, gitas-on sa session, katulog, o tambal.Ing pamagsulat nung kapilan mayayari ing pamagkalabu ning isip — bayu, kabang, o kaibat ning dialysis — tutulung king team bang abalu nung bage ning sanhi ing pamaglako danum, kabaluan ning session, tulug, o gamot.

🚨

If it happens during dialysisKung mangyari habang nagda-dialysisKung mahitabo panahon sa dialysisNung mayari kabang magda-dialysis

Sudden confusion, slurred speech, facial droop, arm weakness, or a seizure during or after dialysis is an emergency. Alert the staff immediately. A normal blood pressure or fluid-removal number does not rule out a stroke.Ang biglaang kalituhan, bulol na pananalita, nakalaylay na mukha, mahinang braso, o kombulsyon habang o pagkatapos ng dialysis ay emergency. Abisuhan agad ang staff. Hindi inaalis ng normal na presyon o numero ng tubig na inalis ang posibilidad ng stroke.Ang kalit nga kalibog, bulol nga pagsulti, nahuyhoy nga nawong, huyang nga bukton, o kombulsyon samtang o human sa dialysis usa ka emergency. Pahibal-a dayon ang staff. Ang normal nga presyon o numero sa tubig nga gikuha dili makawagtang sa posibilidad sa stroke.Ing biglang kalituan, bulol a pamanyalita, melaylay a lupa, malambut a gamat, o kombulsyon kabang o kaibat ning dialysis emergency ya. Abisuan me agad ing staff. E na alisan ning normal a presyon o numeru ning danum a mekwa ing posibilidad ning stroke.

Illustration of a person on a hemodialysis chair with a transparent head showing brain blood flow, a fluid-removal gauge, and a blood-pressure trace that dips mid-session, with a nurse checking in.

During hemodialysis, fluid is removed from the blood. If too much is removed too quickly, blood flow to the brain can dip for a while, sometimes without an obvious drop on the blood-pressure monitor.Sa hemodialysis, inaalis ang tubig mula sa dugo. Kapag sobra at masyadong mabilis ang pag-alis, maaaring pansamantalang bumaba ang daloy ng dugo sa utak, minsan nang walang halatang pagbaba sa monitor ng presyon.Sa hemodialysis, gikuha ang tubig gikan sa dugo. Kung sobra ug paspas kaayo ang pagkuha, mahimong mius-os sa makadiyot ang agos sa dugo sa utok, usahay bisan walay klaro nga pag-us-os sa monitor sa presyon.King hemodialysis, alisan ing danum manibat king daya. Nung sobra at mabilis ing pamaglako, malyaring mababa pansamantala ing dalan ning daya king utak, kapilan e malino ing pamagbaba king monitor ning presyon.

HD
Hemodialysis
UF
Ultrafiltration — fluid removal during dialysis
BP
Blood pressure

Looking for causes that can be fixedPaghahanap ng mga sanhing maaaring ayusinPagpangita sa mga hinungdan nga matul-idPamanintun kareng sanhing malyaring ayusan

A good assessment starts with a conversation. Your doctor will ask what changed, when it started, and how it affects daily life, and, with your permission, will ask someone who knows you well. A short pen-and-paper thinking test may be used. It is one piece of information: it cannot diagnose dementia by itself, and a low score on a bad day, during illness, or right after dialysis can be misleading.Nagsisimula ang mabuting pagsusuri sa pakikipag-usap. Itatanong ng doktor kung ano ang nagbago, kailan nagsimula, at paano ito nakakaapekto sa araw-araw, at, kung papayag ka, magtatanong sa taong lubos na nakakakilala sa iyo. Maaaring gumamit ng maikling test sa pag-iisip gamit ang papel at panulat. Isa lamang itong bahagi ng impormasyon: hindi nito kayang mag-diagnose ng dementia nang mag-isa, at nakakalito ang mababang marka sa masamang araw, habang may sakit, o pagkatapos agad ng dialysis.Ang maayong pagsusi magsugod sa pakigsulti. Pangutan-on sa doktor kung unsay nausab, kanus-a nagsugod, ug unsaon niini pag-apekto sa adlaw-adlaw, ug, kung motugot ka, mangutana sa tawo nga nakaila kanimo pag-ayo. Mahimong gamiton ang mubo nga pagsulay sa panghunahuna gamit ang papel ug ballpen. Usa ra kini ka bahin sa impormasyon: dili kini maka-diagnose og dementia nga kini ra, ug makalibog ang ubos nga marka sa daotang adlaw, samtang masakiton, o dayon human sa dialysis.Mamagumpisa ing mayap a pamanyalidiri king pamisabi. Kutnan na ning doktor nung nanu ing mibayu, kapilan migumpisa, at nung kapilan na apektuan ing aldo-aldo, at, nung pumayag ka, kutnan na ing taung kilala ka. Malyaring gamitan ing maikli a test king pamanisip gamit ing papel at pluma. Metung mu yang bage ning impormasyun: e na kaya ing mag-diagnose dementia bukud, at makalitu ing mababang marka king malating aldo, kabang masakit, o kaibat mismu ning dialysis.

The team will usually review:Karaniwang susuriin ng team ang:Kasagaran susihon sa team ang:Karaniwan suriyan ning team ing:

If the problem keeps progressing, looks unusual, or makes daily tasks unsafe, your doctor may arrange brain imaging or referral to a neurologist, geriatrician, or psychiatrist. That is good care, not a sign that hope is lost.Kung patuloy na lumalala ang problema, kakaiba ang hitsura, o ginagawang hindi ligtas ang araw-araw na gawain, maaaring ipa-scan ng doktor ang utak o i-refer sa neurologist, geriatrician, o psychiatrist. Mabuting pangangalaga ito, hindi senyales na wala nang pag-asa.Kung padayon nga mograbe ang problema, talagsaon ang hitsura, o himoon nga dili luwas ang adlaw-adlaw nga buluhaton, mahimong ipa-scan sa doktor ang utok o i-refer sa neurologist, geriatrician, o psychiatrist. Maayong pag-atiman kini, dili timaan nga wala nay paglaum.Nung patuloy yang lumala ing problema, kakaiba ing anyu, o gawan nang e ligtas ing obra aldo-aldo, malyari nang ipa-scan ning doktor ing utak o i-refer king neurologist, geriatrician, o psychiatrist. Mayap a pamag-asikasu ini, e senyales a ala nang pag-asa.

Medicines that can cloud thinking when kidneys are weakMga gamot na maaaring magpalabo ng isip kapag mahina ang batoMga tambal nga makapahanap sa hunahuna kung huyang ang kidneyGamot a malyari dang pakalabuan ing isip nung malambut ing batu

Weak kidneys remove some medicines more slowly, so a normal dose can build up. Older adults and people on dialysis are most at risk. In one large study of older adults with CKD, starting the muscle relaxant baclofen at a higher dose was linked to about three and a half times more hospital stays for confusion than a lower dose. The overall risk was still small, but the pattern shows why doses must be matched to kidney function.Mas mabagal na inaalis ng mahinang bato ang ilang gamot, kaya maaaring maipon ang normal na dosis. Pinakananganganib ang matatanda at nagda-dialysis. Sa isang malaking pag-aaral sa matatandang may CKD, ang pagsisimula ng muscle relaxant na baclofen sa mas mataas na dosis ay naiugnay sa mga tatlo at kalahating beses na mas maraming pagka-ospital dahil sa kalituhan kumpara sa mas mababang dosis. Maliit pa rin ang kabuuang panganib, pero ipinapakita nito kung bakit dapat itugma ang dosis sa gana ng bato.Ang huyang nga kidney mas hinay nga mokuha sa pipila ka tambal, busa ang normal nga dosis mahimong motapok. Labing delikado ang mga tigulang ug ang nagda-dialysis. Sa usa ka dakong pagtuon sa mga tigulang nga adunay CKD, ang pagsugod sa muscle relaxant nga baclofen sa mas taas nga dosis nalambigit sa mga tulo ug tunga ka pilo nga mas daghang pagka-ospital tungod sa kalibog kumpara sa mas ubos nga dosis. Gamay gihapon ang kinatibuk-ang peligro, apan gipakita niini kung nganong kinahanglan itugma ang dosis sa gana sa kidney.Mas mabagal alisan ning malambut a batu ing aliwang gamot, kaya malyaring mipun ing normal a dosis. Pekamapanganib la reng matatua at magda-dialysis. King metung a maragul a pamag-aral kareng matua a atin CKD, ing pamagumpisa ning muscle relaxant a baclofen king mas matas a dosis meugnay king malapit atlu at kalahating besis a mas dakal a pamag-ospital uli ning kalituan kesa king mas mababang dosis. Malati pa rin ing kabuuang panganib, oneng ipakit na nung nanu ya at dapat itugma ing dosis king gana ning batu.

Overhead photo of a woven market bag spilling out prescription bottles, cold and allergy tablets, sleep aids, herbal capsules, and a handwritten medicine list, with the reminder to bring every medicine to the visit.

Bring every medicine to your visit, including cold and allergy tablets, sleep aids, and herbal products. Some of these stay in the body longer when the kidneys are weak and can cloud thinking.Dalhin ang bawat gamot sa konsulta, kasama ang gamot sa sipon at allergy, pampatulog, at herbal. Mas matagal na nananatili sa katawan ang ilan dito kapag mahina ang bato at maaaring magpalabo ng isip.Dad-a ang matag tambal sa konsulta, lakip ang tambal sa sip-on ug allergy, pampakatulog, ug herbal. Mas dugay magpabilin sa lawas ang pipila niini kung huyang ang kidney ug makapahanap sa hunahuna.Darang me ing balang gamot king konsulta, kayabe ing gamot king sipun at allergy, pampatudtud, at herbal. Mas matagal manatili king katawan ing aliwa kareni nung malambut ing batu at malyari dang pakalabuan ing isip.

Medicine groupGrupo ng gamotGrupo sa tambalGrupu ning gamotExamplesHalimbawaPananglitanAlimbawaWhy it mattersBakit mahalagaNgano importanteNanu ya at mayalaga
Older antihistamines (in many sleep aids and cold or allergy tablets)Lumang antihistamine (nasa maraming pampatulog at gamot sa sipon o allergy)Karaan nga antihistamine (anaa sa daghang pampakatulog ug tambal sa sip-on o allergy)Matuang antihistamine (atyu king dakal a pampatudtud at gamot king sipun o allergy)diphenhydramine, chlorphenamine (chlorpheniramine)Anticholinergic effects can cause confusion, especially in older adultsAng anticholinergic na epekto ay maaaring magdulot ng kalituhan, lalo na sa matatandaAng anticholinergic nga epekto makahatag og kalibog, labi na sa mga tigulangIng anticholinergic a epektu malyari yang magdulot kalituan, lalu na kareng matua
Muscle relaxantsMuscle relaxantMuscle relaxantMuscle relaxantbaclofenCleared by the kidneys; linked to hospital stays for confusion in CKDInaalis ng bato; naiugnay sa pagka-ospital dahil sa kalituhan sa CKDGikuha sa kidney; nalambigit sa pagka-ospital tungod sa kalibog sa CKDAlisan ning batu; meugnay king pamag-ospital uli ning kalituan king CKD
Nerve-pain medicinesGamot sa sakit ng ugatTambal sa sakit sa ugatGamot king sakit ning ugatgabapentin, pregabalinNeed lower doses in CKD; can cause drowsiness and unsteadinessKailangan ng mas mababang dosis sa CKD; maaaring magdulot ng antok at pagkahiloKinahanglan og mas ubos nga dosis sa CKD; makahatag og katulgon ug pagkalipongKailangan mas mababang dosis king CKD; malyari yang magdulot antuk at kalipung
Sleeping pills and tranquilizersPampatulog at pampakalmaPampakatulog ug pampakalmaPampatudtud at pampakalmabenzodiazepines such as diazepambenzodiazepine gaya ng diazepambenzodiazepine sama sa diazepambenzodiazepine antimo ing diazepamSlow thinking and raise the risk of fallsNagpapabagal ng isip at nagpapataas ng panganib na matumbaMakapahinay sa hunahuna ug makapataas sa peligro nga matumbaPabagalan ing isip at pataasan ing panganib a mabagsak
Strong pain medicinesMatapang na gamot sa sakitKusog nga tambal sa sakitMatapang a gamot king sakitopioids such as tramadolopioid gaya ng tramadolopioid sama sa tramadolopioid antimo ing tramadolSome build up in kidney failure; need careful dosingMay naiipon sa kidney failure; kailangan ng maingat na dosisAdunay motapok sa kidney failure; kinahanglan og mabinantayon nga dosisAtin mipun king kidney failure; kailangan maingat a dosis
⚠️

Do not stop a medicine on your ownHuwag ihinto ang gamot nang mag-isaAyaw hunonga ang tambal nga ikaw raE me tuknangan ing gamot bukud

Some of these medicines are needed, and stopping suddenly can be harmful. Bring every bottle and packet, including herbal products, to your next visit, and ask your doctor or pharmacist whether each one is still needed and at the right dose for your kidneys. Many cold and allergy tablets sold in pharmacies contain chlorphenamine, so read the label.Kailangan ang ilan sa mga gamot na ito, at maaaring makasama ang biglang paghinto. Dalhin ang bawat bote at pakete, kasama ang herbal, sa susunod na konsulta, at itanong sa doktor o pharmacist kung kailangan pa ang bawat isa at kung tama ang dosis para sa iyong bato. Maraming gamot sa sipon at allergy sa botika ang may chlorphenamine, kaya basahin ang label.Kinahanglan ang pipila niini nga mga tambal, ug makadaot ang kalit nga paghunong. Dad-a ang matag botelya ug pakete, lakip ang herbal, sa sunod nga konsulta, ug pangutan-a ang doktor o pharmacist kung kinahanglan pa ang matag usa ug kung husto ang dosis para sa imong kidney. Daghang tambal sa sip-on ug allergy sa botika ang adunay chlorphenamine, busa basaha ang label.Kailangan ing aliwa kareng gamot a reni, at malyaring makasakit ing biglang pamagtuknang. Darang me ing balang bote at pakete, kayabe ing herbal, king susunod a konsulta, at kutnan me ing doktor o pharmacist nung kailangan pa ing balang metung at nung tama ing dosis para king batu mu. Dakal a gamot king sipun at allergy king botika ing atin chlorphenamine, kaya basan me ing label.

Things that protect your brain and your kidneys togetherMga bagay na sabay na nagpoprotekta sa iyong utak at batoMga butang nga dungan nga manalipod sa imong utok ug kidneyBage a kayabe dang protektan ing utak at batu mu

No medicine is yet proven to prevent or reverse thinking problems caused by kidney disease. But the steps that protect blood vessels and kidneys are reasonable for the brain too, and most are worth doing for their own sake:Wala pang gamot na napatunayang pumipigil o nagbabalik sa problema sa pag-iisip dahil sa sakit sa bato. Pero ang mga hakbang na nagpoprotekta sa ugat at bato ay makatwiran din para sa utak, at karamihan ay sulit gawin para sa sarili nilang benepisyo:Wala pay tambal nga napamatud-an nga mopugong o mobalik sa problema sa panghunahuna tungod sa sakit sa kidney. Apan ang mga lakang nga manalipod sa ugat ug kidney makatarunganon usab para sa utok, ug kadaghanan angay buhaton para sa ilang kaugalingong kaayohan:Ala pang gamot a mepatunayang pigilan o ibalik ing problema king pamanisip uli ning sakit king batu. Oneng deng hakbang a protektan ing ugat at batu makatuyu la rin para king utak, at kalupan mayap gawan para king sarili dang benepisyu:

Circular action wheel around a brain and kidneys labeled protect both, with eight steps: control blood pressure, steady blood sugar, take kidney medicines, move every day, check hearing and eyes, stay connected, sleep and mood, and treat anemia.

The steps that protect your blood vessels and kidneys are also sensible for your brain. None is proven to prevent memory problems on its own, but each is worth doing for your health.Ang mga hakbang na nagpoprotekta sa iyong ugat at bato ay makatwiran din para sa iyong utak. Wala pang napatunayang pumipigil sa problema sa memorya nang mag-isa, pero sulit gawin ang bawat isa para sa iyong kalusugan.Ang mga lakang nga manalipod sa imong ugat ug kidney makatarunganon usab para sa imong utok. Wala pay napamatud-an nga mopugong sa problema sa memorya nga kini ra, apan angay buhaton ang matag usa para sa imong panglawas.Deng hakbang a protektan ing ugat at batu mu makatuyu la rin para king utak mu. Ala pang mepatunayang pigilan ing problema king memorya bukud, oneng mayap gawan ing balang metung para king kalusugan mu.

New treatments: what we know so farMga bagong gamutan: ang alam natin sa ngayonMga bag-ong pagtambal: ang atong nahibal-an karonBayung panulu: ing balu tamu ngeni

Four-step evidence ladder: not for memory (detox products, most supplements); did not help thinking (cooler dialysate, more sessions alone, semaglutide in Alzheimer disease); needs confirmation (B vitamins, one study); promising (exercise plus brain training, hemodiafiltration).

Not every new treatment is equally proven. Exercise with brain training and hemodiafiltration show promising signals; others did not help thinking or still need confirmation. Promising does not mean proven.Hindi pare-pareho ang patunay sa bawat bagong gamutan. Maaasahan ang ehersisyo na may brain training at ang hemodiafiltration; ang iba ay hindi nakatulong sa pag-iisip o kailangan pang makumpirma. Ang maaasahan ay hindi pa nangangahulugang napatunayan.Dili parehas ang pamatuod sa matag bag-ong pagtambal. Maayo ang dagway sa ehersisyo nga adunay brain training ug sa hemodiafiltration; ang uban wala makatabang sa panghunahuna o kinahanglan pa makumpirma. Ang maayo ang dagway dili pa nagpasabot nga napamatud-an.E pare-pareu ing patunay king balang bayung panulu. Maasahan ing ehersisyu a atin brain training at ing hemodiafiltration; deng aliwa e la mekatulung king pamanisip o kailangan pang makumpirma. Ing maasahan e pa buring sabian a mepatunayan.

ApproachParaanPamaagiParalanWhat studies foundAng natuklasan ng pag-aaralAng nakaplagan sa pagtuonIng akit da ring pamag-aralWhere it standsKalagayanKahimtangKalagayan
Hemodiafiltration (HDF), a type of dialysis that removes more large waste moleculesHemodiafiltration (HDF), isang uri ng dialysis na nag-aalis ng mas maraming malalaking dumiHemodiafiltration (HDF), usa ka matang sa dialysis nga mokuha og mas daghang dagkong hugawHemodiafiltration (HDF), metung a klasi ning dialysis a alisan ing mas dakal a maragul a dinatIn a large trial, people on HDF reported a slower decline in their own thinking over about 2½ years than people on standard high-flux HDSa isang malaking trial, ang mga nasa HDF ay nag-ulat ng mas mabagal na paghina ng sariling pag-iisip sa loob ng mga 2½ taon kaysa sa nasa karaniwang high-flux HDSa usa ka dakong trial, ang mga anaa sa HDF nagreport og mas hinay nga paghuyang sa kaugalingong panghunahuna sulod sa mga 2½ ka tuig kaysa sa anaa sa kasagarang high-flux HDKing metung a maragul a trial, deng atyu king HDF mag-report mas mabagal a pamaglambut ning sariling pamanisip king lagyu 2½ banwa kesa kareng atyu king karaniwang high-flux HDPromising; based on how people rated themselves, not on memory testsMaaasahan; batay sa sariling pagtatasa, hindi sa test ng memoryaMaayo ang dagway; base sa kaugalingong pagtimbang, dili sa pagsulay sa memoryaMaasahan; batay king sariling pamagtasa, e king test ning memorya
Exercise and brain training during dialysisEhersisyo at brain training habang nagda-dialysisEhersisyo ug brain training panahon sa dialysisEhersisyu at brain training kabang magda-dialysisBetter global thinking score after three months in a small trial; the main planning test did not improveMas magandang marka sa pangkalahatang pag-iisip pagkatapos ng tatlong buwan sa maliit na trial; hindi bumuti ang pangunahing test sa pagpaplanoMas maayo nga marka sa kinatibuk-ang panghunahuna human sa tulo ka bulan sa gamay nga trial; wala miuswag ang nag-unang pagsulay sa pagplanoMas mayap a marka king pangkalahatang pamanisip kaibat ning atlung bulan king malati a trial; e mi-unlad ing pangunahing test king pamagplanuEncouraging, safe, and good for overall healthNakakahikayat, ligtas, at mabuti sa pangkalahatang kalusuganMakapadasig, luwas, ug maayo sa kinatibuk-ang panglawasMakapagsikan, ligtas, at mayap king pangkalahatang kalusugan
Cooler dialysate or more frequent sessionsMas malamig na dialysate o mas madalas na sessionMas bugnaw nga dialysate o mas kanunay nga sessionMas malamig a dialysate o mas maralas a sessionSmall or older trials did not show better thinkingHindi nagpakita ng mas magandang pag-iisip ang maliliit o lumang trialWala nagpakita og mas maayo nga panghunahuna ang gagmay o karaan nga trialE la pekit mas mayap a pamanisip deng malati o matuang trialNot proven for thinking; may still be used for other reasonsHindi napatunayan para sa pag-iisip; maaari pa ring gamitin sa ibang dahilanWala napamatud-an para sa panghunahuna; mahimo gihapong gamiton sa laing rasonE mepatunayan para king pamanisip; malyari pa ring gamitan king aliwang dahilan
Kidney transplantKidney transplantKidney transplantKidney transplantSome memory and speed measures improve after transplant; overall thinking scores often stay similarBumubuti ang ilang sukat ng memorya at bilis pagkatapos ng transplant; madalas pareho ang pangkalahatang markaMuuswag ang pipila ka sukod sa memorya ug kapaspas human sa transplant; kasagaran parehas ang kinatibuk-ang markaMumayap ing aliwang sukat ning memorya at bilis kaibat ning transplant; maralas pareu ing pangkalahatang markaA thinking test alone should not decide transplant eligibilityHindi dapat ang test sa pag-iisip lamang ang magpasya kung puwede sa transplantDili angay nga ang pagsulay sa panghunahuna ra ang modesisyon kung puwede sa transplantE dapat ing test king pamanisip mu ing magpasiya nung malyari king transplant
B vitamins (thiamin with folic acid)B vitamins (thiamin at folic acid)B vitamins (thiamin ug folic acid)B vitamins (thiamin at folic acid)One 2026 trial in people on hemodialysis reported better thinking scores after nearly two yearsIsang trial noong 2026 sa mga nagda-hemodialysis ang nag-ulat ng mas magandang marka pagkatapos ng halos dalawang taonUsa ka trial sa 2026 sa mga nagda-hemodialysis ang nagreport og mas maayo nga marka human sa hapit duha ka tuigMetung a trial king 2026 kareng magda-hemodialysis ing mag-report mas mayap a marka kaibat ning malapit adwang banwaNeeds confirmation before it becomes standard; ask before taking high dosesKailangang makumpirma bago maging pamantayan; magtanong muna bago uminom ng mataas na dosisKinahanglan makumpirma una mahimong sumbanan; pangutana una sa dili pa moinom og taas nga dosisKailangan pang makumpirma bayu maging pamantayan; magkutang muna bayu uminum matas a dosis
Gut-toxin binders, probiotics, "detox" productsGut-toxin binder, probiotic, mga produktong "detox"Gut-toxin binder, probiotic, mga produkto nga "detox"Gut-toxin binder, probiotic, produktung "detox"May change lab markers; no proven benefit for thinking in peopleMaaaring baguhin ang lab marker; walang napatunayang benepisyo sa pag-iisip ng taoMahimong usbon ang lab marker; walay napamatud-an nga kaayohan sa panghunahuna sa tawoMalyari nang bayuan ing lab marker; ala mepatunayang benepisyu king pamanisip ning tauNot recommended for memory; some herbal "detox" products can harm the kidneysHindi inirerekomenda para sa memorya; may herbal na "detox" na maaaring makasira sa batoDili girekomenda para sa memorya; adunay herbal nga "detox" nga makadaot sa kidneyE irekomenda para king memorya; atin herbal a "detox" a malyaring makasira king batu
Diabetes and weight medicines (semaglutide)Gamot sa diabetes at timbang (semaglutide)Tambal sa diabetes ug timbang (semaglutide)Gamot king diabetes at timbang (semaglutide)Two large trials in early Alzheimer disease found no slowing of declineWalang nakitang pagbagal ng paghina sa dalawang malaking trial sa maagang Alzheimer diseaseWalay nakita nga paghinay sa paghuyang sa duha ka dakong trial sa sayong Alzheimer diseaseAla akit pamagbagal ning pamaglambut king adwang maragul a trial king maagang Alzheimer diseaseUse for kidneys, heart, and diabetes when indicated, not for memoryGamitin para sa bato, puso, at diabetes kung kailangan, hindi para sa memoryaGamita para sa kidney, kasingkasing, ug diabetes kung gikinahanglan, dili para sa memoryaGamitan para king batu, pusu, at diabetes nung kailangan, e para king memorya

How families and caregivers can helpPaano makakatulong ang pamilya at tagapag-alagaUnsaon pagtabang sa pamilya ug tig-atimanNung kapilan makatulung ing pamilya at tagapag-asikasu

Photo of a Filipino grandfather explaining his weekly pill organizer to his teenage granddaughter, who points to a simple handwritten plan, with a phone alarm and a glass of water on the table.

Simple tools help: a weekly pill organizer, a short written plan, phone reminders, and teach-back, where the patient explains the plan in their own words. The patient stays in charge.Nakakatulong ang simpleng kagamitan: lingguhang pill organizer, maikling nakasulat na plano, paalala sa telepono, at teach-back, kung saan ipinapaliwanag ng pasyente ang plano sa sarili niyang salita. Ang pasyente pa rin ang may hawak.Makatabang ang simple nga himan: semana-semana nga pill organizer, mubo nga sinulat nga plano, pahinumdom sa telepono, ug teach-back, diin ipasabot sa pasyente ang plano sa iyang kaugalingong pulong. Ang pasyente gihapon ang nagdumala.Makatulung ing simpleng kasangkapan: lingguhang pill organizer, maikling nakasulat a planu, paalala king telepunu, at teach-back, nung nu ipaliwanag ning pasyente ing planu king sariling amanu na. Ing pasyente pa rin ing mamaun.

Use this checklist before a visit. Copy it, fill it in, and bring it. It needs no names or identification numbers.Gamitin ang checklist na ito bago ang konsulta. Kopyahin, sagutan, at dalhin. Hindi kailangan ng pangalan o ID number.Gamita kini nga checklist sa dili pa ang konsulta. Kopyaha, sulati, ug dad-a. Dili kinahanglan og ngalan o ID number.Gamitan me ing checklist a ini bayu ing konsulta. Kopyan, sagutan, at darang. E kailangan lagyu o ID number.

Copy-ready checklist:Checklist na handang kopyahin:Checklist nga andam kopyahon:Checklist a makasadyang kopyan:

WHAT CHANGED — bring to my next visit What I or my family noticed: ___ When it started (date or season): ___ Sudden or slow? ___ Comes and goes? Y / N Timing with dialysis: before / during / after / not on dialysis New or changed medicines (include cold, allergy, sleep, pain, herbal): ___ Recent illness, fever, fall, or hospital stay: ___ Sleep: snoring / waking often / sleepy in the day Mood: low / worried / OK Hearing or eyesight problems: ___ Daily tasks that are harder now (medicines, money, meals, appointments): ___ Help I would like: ___ANO ANG NAGBAGO — dalhin sa susunod kong konsulta Ang napansin ko o ng pamilya: ___ Kailan nagsimula (petsa o panahon): ___ Biglaan o dahan-dahan? ___ Dumarating at nawawala? O / H Oras kaugnay ng dialysis: bago / habang / pagkatapos / hindi nagda-dialysis Bago o binagong gamot (kasama sa sipon, allergy, tulog, sakit, herbal): ___ Kamakailang sakit, lagnat, pagkatumba, o pagka-ospital: ___ Tulog: humihilik / madalas magising / inaantok sa araw Damdamin: malungkot / nag-aalala / OK Problema sa pandinig o paningin: ___ Gawaing mas mahirap na ngayon (gamot, pera, pagkain, appointment): ___ Tulong na gusto ko: ___UNSAY NAUSAB — dad-on sa akong sunod nga konsulta Ang akong namatikdan o sa pamilya: ___ Kanus-a nagsugod (petsa o panahon): ___ Kalit o hinay-hinay? ___ Moabot ug mawala? O / D Oras kalabot sa dialysis: sa wala pa / samtang / human / wala nagda-dialysis Bag-o o giusab nga tambal (lakip sa sip-on, allergy, katulog, sakit, herbal): ___ Bag-ohay nga sakit, hilanat, pagkatumba, o pagka-ospital: ___ Katulog: maghagok / kanunay makamata / katulgon sa adlaw Pagbati: masulub-on / nabalaka / OK Problema sa pandungog o panan-aw: ___ Buluhaton nga mas lisod na karon (tambal, kwarta, pagkaon, appointment): ___ Tabang nga gusto nako: ___NANU ING MIBAYU — darang king susunod kung konsulta Ing apansin ku o ning pamilya: ___ Kapilan migumpisa (petsa o panaun): ___ Biglaan o dahan-dahan? ___ Dadatang at mawawala? O / E Oras kaugnay ning dialysis: bayu / kabang / kaibat / e magda-dialysis Bayu o mibayung gamot (kayabe king sipun, allergy, tulug, sakit, herbal): ___ Kapilan pang sakit, lagnat, pamagbagsak, o pamag-ospital: ___ Tulug: mangungurut / maralas magising / mangantuk king aldo Damdamin: malungkut / mabalisa / OK Problema king pamakiramdam o pamanlawe: ___ Obra a mas masakit ngeni (gamot, pera, pamangan, appointment): ___ Tulung a buri ku: ___

Questions to ask your kidney teamMga tanong para sa iyong kidney teamMga pangutana para sa imong kidney teamKutang para king kidney team mu

Questions patients often askMga tanong na madalas itanong ng pasyenteMga pangutana nga kanunay ipangutana sa pasyenteKutang a maralas kutnan da ring pasyente

Does kidney disease mean I will get dementia?Ibig bang sabihin ng sakit sa bato na magkaka-dementia ako?Nagpasabot ba ang sakit sa kidney nga mag-dementia ko?Buri na bang sabian ning sakit king batu a magka-dementia ku?
No. Kidney disease raises the risk on average, but most people with CKD do not develop dementia, and many thinking changes are mild or have treatable causes.Hindi. Pinapataas ng sakit sa bato ang panganib sa karaniwan, pero karamihan sa may CKD ay hindi nagkaka-dementia, at maraming pagbabago sa pag-iisip ang banayad o may nagagamot na sanhi.Dili. Ang sakit sa kidney mopataas sa peligro sa kasagaran, apan kadaghanan sa adunay CKD dili mag-dementia, ug daghang kausaban sa panghunahuna ang hinay o adunay matambalan nga hinungdan.Ali. Pataasan ning sakit king batu ing panganib king karaniwan, oneng kalupan kareng atin CKD e magka-dementia, at dakal a pamagbayu king pamanisip ing banayad o atin sanhing malyaring panuluan.
Will starting dialysis make my thinking better or worse?Bubuti ba o lalala ang pag-iisip ko kapag nagsimula ng dialysis?Muayo ba o mograbe ang akong panghunahuna kung magsugod og dialysis?Mumayap ba o lumala ing pamanisip ku nung migumpisa ku dialysis?
It depends. When symptoms come from kidney failure itself, starting dialysis can clear them. Over the long term, the effect varies, which is why fluid removal and blood pressure during sessions are watched closely.Depende. Kapag ang sintomas ay galing mismo sa kidney failure, maaaring mawala ito sa pagsisimula ng dialysis. Sa pangmatagalan, nag-iiba ang epekto, kaya binabantayang mabuti ang pag-alis ng tubig at presyon habang nagda-dialysis.Depende. Kung ang sintomas gikan mismo sa kidney failure, mahimong mawala kini sa pagsugod sa dialysis. Sa dugay nga panahon, lahi-lahi ang epekto, mao nga gibantayan pag-ayo ang pagkuha sa tubig ug presyon panahon sa dialysis.Depende. Nung ing sintomas manibat mismu king kidney failure, malyari lang mawala king pamagumpisa ning dialysis. King matagal a panaun, aliwa-aliwa ing epektu, kaya babantayan mayap ing pamaglako danum at presyon kabang magda-dialysis.
Should I take memory supplements?Dapat ba akong uminom ng supplement para sa memorya?Angay ba ko moinom og supplement para sa memorya?Dapat ku bang uminum supplement para king memorya?
Not without asking your kidney doctor. None is proven for kidney-related thinking problems, and some products contain potassium, phosphorus, or herbs that can harm the kidneys.Hindi nang hindi nagtatanong sa iyong kidney doctor. Wala pang napatunayan para sa problema sa pag-iisip na kaugnay ng bato, at may produktong may potassium, phosphorus, o halamang-gamot na maaaring makasira sa bato.Dili nga dili mangutana sa imong kidney doctor. Wala pay napamatud-an para sa problema sa panghunahuna nga may kalabotan sa kidney, ug adunay produkto nga adunay potassium, phosphorus, o tanom nga makadaot sa kidney.Ali nung e ka magkutang king kidney doctor mu. Ala pang mepatunayan para king problema king pamanisip a kaugnay ning batu, at atin produktung atin potassium, phosphorus, o tanaman a malyaring makasira king batu.
Is it normal to feel foggy after dialysis?Normal ba ang malabong isip pagkatapos ng dialysis?Normal ba ang hanap nga hunahuna human sa dialysis?Normal ba ing malabung isip kaibat ning dialysis?
It is common but not something to accept silently. Tell the team, because changes to fluid removal, session length, or medicines can sometimes help.Karaniwan ito pero hindi dapat tanggapin nang tahimik. Sabihin sa team, dahil minsan nakakatulong ang pagbabago sa pag-alis ng tubig, haba ng session, o gamot.Kasagaran kini apan dili angay dawaton nga hilom. Isulti sa team, kay usahay makatabang ang kausaban sa pagkuha sa tubig, gitas-on sa session, o tambal.Karaniwan ya oneng e dapat tanggapan a tahimik. Sabian mu king team, uling kapilan makatulung ing pamagbayu king pamaglako danum, kabaluan ning session, o gamot.
Can a low test score stop me from getting a transplant?Mapipigilan ba ako ng mababang marka sa test na magka-transplant?Mapugngan ba ko sa ubos nga marka sa pagsulay nga ma-transplant?Malyari na kung pigilan ning mababang marka king test a ma-transplant?
A thinking test alone should not decide this. Teams look at the whole picture, including support at home and the ability to take medicines reliably, and they help with both.Hindi dapat ang test sa pag-iisip lamang ang magpasya rito. Tinitingnan ng team ang buong larawan, kasama ang suporta sa bahay at kakayahang uminom ng gamot nang maayos, at tumutulong sila sa dalawang ito.Dili angay nga ang pagsulay sa panghunahuna ra ang modesisyon niini. Tan-awon sa team ang tibuok hulagway, lakip ang suporta sa balay ug abilidad sa pag-inom og tambal nga maayo, ug motabang sila sa duha.E dapat ing test king pamanisip mu ing magpasiya kaniti. Lawen ning team ing buung larawan, kayabe ing suporta king bale at kakayanan a uminum gamot a mayap, at tumulung la king adwang ini.

The kidney–brain axis: a convergence model

Cognitive impairment in chronic kidney disease (CKD) is common, under-recognized, and clinically consequential: it erodes the very skills (planning, sustained attention, working memory) that complex kidney care demands, and it is associated with nonadherence, hospitalization, withdrawal from dialysis, and death. The useful mental model is convergence rather than a single "uremic" lesion. Shared small-vessel disease, retained solutes, dialysis-related hemodynamic stress, and a background of inflammation, anemia, sleep and mood disorders, and drug accumulation overlap within the same patient, in proportions that differ from person to person.

The dominant domains are executive function, attention, and processing speed, a frontal-subcortical "vascular" profile; memory is involved less consistently. That profile matters at the bedside, because a screening instrument weighted toward recall can miss impairment that is real and functionally important. It also explains why the problem is easy to misattribute to fatigue, depression, or "noncompliance".

This guide separates four rungs of certainty throughout: established physiology, randomized evidence on patient-important outcomes, observational associations, and mechanistic hypotheses. Most of the kidney–brain literature sits on the third and fourth rungs. No therapy has yet been shown in a definitive randomized trial to prevent or reverse CKD-associated cognitive decline, so management today rests on treating identifiable contributors and protecting the vascular bed that the kidney and brain share.

🔬

Evidence labels used in this guide

Each claim is tagged by design (guideline, randomized trial, observational association, mechanism) and by outcome class (diagnosed dementia, objective cognitive test, patient-reported cognition, biomarker or imaging, kidney or cardiovascular outcome). A randomized trial with a biomarker or patient-reported endpoint is still a biomarker or patient-reported finding. These labels describe directness, not formal Grading of Recommendations Assessment, Development and Evaluation (GRADE) ratings; guideline grades are quoted in each body's own vocabulary.

How common, in whom, and what the risk markers mean

Prevalence. A 2024 systematic review and meta-analysis (50 studies, 25,289 adults) reported a pooled prevalence of cognitive impairment of 40% (95% confidence interval [CI] 33–46%), with attention and executive dysfunction the most common manifestations. Estimates rose with age, diabetes, and hypertension. Heterogeneity was extreme (I² 99%) and publication bias was present, because instruments, cutoffs, languages, and samples differ; treat these as screen-defined burden, not diagnosed dementia.

PopulationPooled prevalence (95% CI)What it can and cannot tell you
Nondialysis CKD32% (25–38%)Burden rises across CKD stages; a meta-analytic average across instruments
Maintenance hemodialysis (HD)53% (38–69%)Highest burden; HD cohorts are older and carry more cerebrovascular disease
Peritoneal dialysis (PD)39% (26–53%)Lower than HD, but PD selection (younger, more independent) confounds the comparison
Kidney transplant recipients26% (15–38%)Lowest burden; transplant selection excludes many with established impairment
All CKD40% (33–46%)I² 99%; publication bias present; study-defined impairment, not dementia
Dot-and-whisker chart of pooled prevalence of cognitive impairment: nondialysis CKD 32% (25–38%), hemodialysis 53% (38–69%), peritoneal dialysis 39% (26–53%), kidney transplant 26% (15–38%), and all CKD 40% (33–46%), with a note that I-squared was 99% and row differences are not treatment effects.

Pooled prevalence estimates with 95% confidence intervals on a common 0–100% axis (Zhang et al., 2024). Heterogeneity was extreme, and selection differs by modality, so the rows describe screen-defined burden, not the effect of a treatment.

CKD
Chronic kidney disease
I²
Proportion of variation between studies due to heterogeneity

Do not read the modality gradient as a treatment effect. A 2026 meta-analysis of 26 cohort studies (326,216 patients) reported worse cognition (standardized mean difference −0.46) and higher dementia incidence (odds ratio 1.68) with HD than with PD, but every included study was observational and the dementia estimate was highly heterogeneous (I² 94%). Confounding by indication (who is offered and chooses PD) is the leading explanation. Modality choice should remain shared and individualized.

Kidney markers and incident dementia. In 202,702 UK Biobank participants aged 60 years or older (6,042 incident dementia cases over up to 15 years), combined creatinine–cystatin C estimated glomerular filtration rate (eGFR) <60 versus ≥90 mL/min/1.73 m² was associated with a fully adjusted hazard ratio (HR) of 1.42 (1.28–1.58). Urine albumin-to-creatinine ratio (UACR) 3–30 and >30 mg/mmol, versus <3 mg/mmol, carried HRs of 1.16 (1.07–1.26) and 2.24 (1.79–2.80). The Atherosclerosis Risk in Communities (ARIC) cohort independently found albuminuria consistently associated with dementia at midlife and older age, while lower eGFR was associated only when estimated from cystatin C or β₂-microglobulin, not creatinine, a reminder that creatinine-based eGFR in frail, sarcopenic adults can obscure risk. These are relative hazards from cohorts; they are not personal probabilities, and no trial has shown that lowering UACR prevents dementia.

Acute kidney injury (AKI) counts too. A 2026 meta-analysis (49 studies, 11.3 million participants) associated AKI with stroke (pooled adjusted HR 1.35, 1.20–1.52), delirium (adjusted odds ratio 1.76, 1.42–2.17), and dementia (adjusted HR 1.64, 1.41–1.89), with a stage gradient for stroke. The association does not establish causation, but it argues for asking about cognition after an AKI episode, particularly in older adults.

Frailty and modifiable factors. Frail adults with CKD had about three times the odds of cognitive impairment (odds ratio 3.13, 1.92–5.12; 17 studies, 129,868 patients; 2026). An August 2026 UK Biobank CKD cohort (16,083 participants, 806 dementia diagnoses over a mean 13.8 years) found that hypertension, diabetes, depression, hearing loss, and lower leisure or social activity remained associated with dementia after false-discovery-rate adjustment, while moderate physical activity was associated with lower risk. A 2026 umbrella review of hemodialysis cohorts added female sex, diabetes, cerebrovascular disease, low hemoglobin, inflammatory markers, low-flux dialysis, and intradialytic hypotension as correlates; higher education was protective. Only two associations reached moderate certainty. These lists support asking about the factors; they do not show that modifying any single one prevents dementia.

Normal physiology first, then what CKD breaks

Start from normal physiology. The brain and kidney are both low-resistance, high-flow organs that receive continuous perfusion at high volume, protected by autoregulation and by specialized barriers (the glomerular filtration barrier and the blood–brain barrier [BBB]). Their small penetrating arterioles are exposed to near-systemic pressure over a short distance, which makes both beds sensitive to pulsatile load and to the same injuries: hypertension, diabetes, and arterial stiffness. When disease narrows the autoregulatory range, each organ becomes dependent on perfusion pressure in a way that healthy organs are not.

PathwayMechanismStrength of evidence and practical boundary
Shared small-vessel diseaseEndothelial dysfunction and arteriolosclerosis produce white matter hyperintensities, lacunes, and microbleeds; albuminuria is the renal counterpart of the same systemic microvascular injury. White matter injury disrupts frontal-subcortical circuits, slowing processing speed and executive function.Human cohort and imaging data (UK Biobank, ARIC). Mixed vascular and neurodegenerative pathology is common. An eGFR or UACR value does not diagnose a brain disorder.
Retained solutes and the gut–kidney–brain pathwayColonic bacterial metabolism of tryptophan and tyrosine yields precursors of indoxyl sulfate and p-cresyl sulfate. These protein-bound solutes accumulate as GFR falls and are poorly removed by diffusive HD. Experimental work implicates aryl hydrocarbon receptor signaling, oxidative stress, endothelial and BBB dysfunction, and neuroinflammation.Human associations plus animal and in vitro work (2025 JASN review; metabolomic profiling in dialysis). A causal contribution in humans, and a cognition-directed target, remain unproven. Urea clearance (Kt/V) is not a proxy for clearance of protein-bound or middle molecules.
Dialysis-related cerebral hypoperfusionUltrafiltration (UF) and the fall in blood pressure (BP) during HD challenge cerebral autoregulation, whose lower limit varies widely between patients. Transcranial Doppler shows middle cerebral artery flow velocity falling during dialysis in proportion to UF volume.Direct physiology: cerebral desaturation in 23.5% of 635 monitored sessions; BP poorly predicted it; intradialytic cerebral ischemia, but not hypotension, correlated with lower executive function at 12 months (pilot data). Not a measure of stroke or dementia.
Systemic and pharmacologic loadAnemia, inflammation, metabolic acidosis, dysnatremia, hypoglycemia, hyperparathyroidism, sleep apnea, depression, and accumulation of renally cleared central nervous system (CNS)-active drugs lower cognitive reserve or cause frank encephalopathy.Contributions vary; several are reversible once identified. Treat each on its own merits; a symptom checklist cannot apportion causality.

The causal chain therefore runs in both directions. Cognitive impairment degrades medication management, fluid and diet adherence, and attendance; worse control then accelerates kidney and vascular injury. This feedback loop is the clinical reason to screen, simplify regimens, and involve caregivers, even when the underlying lesion cannot be reversed.

Clinician mechanism schematic with four panels: small-vessel disease linking albuminuria and white matter hyperintensities; gut-derived indoxyl sulfate and p-cresyl sulfate crossing a disrupted blood-brain barrier; transcranial Doppler flow velocity and cerebral oxygen saturation falling during ultrafiltration; and accumulation of renally cleared CNS-active drugs, converging on executive dysfunction.

Four converging pathways. Panels mark observed human associations with solid lines and mechanistic hypotheses with dashed lines; none of the panels implies that a single pathway explains cognitive decline in an individual patient.

AhR
Aryl hydrocarbon receptor
BBB
Blood–brain barrier
IS
Indoxyl sulfate
PCS
p-Cresyl sulfate
MCA
Middle cerebral artery
rSO₂
Regional cerebral oxygen saturation
UF
Ultrafiltration
WMH
White matter hyperintensities
🧪

Alzheimer blood biomarkers are kidney-sensitive

A 2026 systematic review (93 studies, 62,503 participants) found lower eGFR associated with higher blood neurofilament light chain, glial fibrillary acidic protein, amyloid-β40, and phosphorylated tau 181, whereas cerebrospinal fluid markers showed no consistent association, suggesting reduced clearance rather than more neurodegeneration. In a 2026 multicenter amyloid positron emission tomography study, standard plasma p-tau217 cutoffs lost accuracy in CKD (accuracy 0.65), improving to 0.83 with a subgroup-specific cutoff. In the Brain in Kidney Disease cohort, serum brain-derived tau rose steeply as eGFR fell, while the p-tau217/brain-derived tau ratio was largely unaffected. Interpret these assays only through specialist, assay-specific pathways; there is no validated renal correction factor, so this guide offers no cutoff tool.

Hours to days: delirium, stroke, and encephalopathy

Tempo is the first branch point. Delirium, stroke, seizure, and metabolic encephalopathy present over hours to days and fluctuate; they demand same-day assessment and override any outpatient screening result.

Acute or fluctuating change (hours to days)
1
Stroke first. Sudden focal deficit, speech disturbance, facial droop, or a new seizure activates the local stroke or emergency pathway immediately, including during or after HD. A BP reading, UF rate, or "probably dialysis-related" explanation cannot exclude stroke.
2
Screen for delirium with a validated tool. In hospital and long-term care, the National Institute for Health and Care Excellence (NICE) guideline CG103 (2023 update) recommends the 4 'A's Test (4AT) when indicators of delirium are noticed, and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the Intensive Care Delirium Screening Checklist (ICDSC) in critical care and post-operative recovery. A positive screen warrants clinical diagnosis; a low score does not override observed acute change. In a 2021 meta-analysis of 17 studies (3,702 observations), the 4AT had pooled sensitivity and specificity of 0.88 each for delirium in older adults; it has not been specifically validated in outpatient dialysis.
3
Search for precipitants. Infection (including access and peritonitis), hypoxia, hypoglycemia, hyponatremia or hypernatremia, hypercalcemia, severe acidosis, urinary retention, constipation, alcohol or sedative withdrawal, and drug toxicity. In advanced CKD, consider uremic encephalopathy; around dialysis initiation, consider dialysis disequilibrium syndrome. Neither diagnosis follows from a single blood urea nitrogen (BUN) or eGFR value.
4
Drug toxicity in reduced clearance. Recognized offenders include baclofen, gabapentinoids, opioid metabolites (morphine, codeine, tramadol), acyclovir and valacyclovir, cefepime and other β-lactams, metoclopramide, lithium, and sedative-hypnotics. In Ontario adults aged 66 years or older with eGFR <60 not on dialysis, starting baclofen at ≥20 vs <20 mg/day was associated with 1.11% vs 0.42% hospitalization with encephalopathy within 30 days (weighted relative risk 3.54, 2.24–5.59; weighted risk difference 0.80%), with the absolute excess rising as eGFR fell. Among older adults on dialysis, encephalopathy hospitalization occurred in 7.2% of new baclofen users versus <0.1% of nonusers.
5
Escalate to nephrology when uremic encephalopathy is suspected. Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidance (Practice Points 5.4.1–5.4.2, ungraded) bases dialysis initiation on a composite assessment and lists neurologic symptoms attributable to uremia among the indications.
Clinical algorithm flowchart branching on tempo: sudden focal signs to the stroke pathway; hours-to-days fluctuating change to delirium screening with the 4AT and a precipitant search including drug toxicity and uremic encephalopathy; weeks-to-months decline to structured assessment with collateral history, reversible-contributor review, a validated cognitive screen at a consistent time relative to dialysis, and specialist referral when progressive or atypical.

Tempo-first pathway. Sudden focal signs go straight to the stroke pathway; fluctuating change is delirium until proven otherwise; gradual decline gets a structured, collateral-informed assessment and a review of reversible contributors.

4AT
4 'A's Test for delirium
CAM-ICU
Confusion Assessment Method for the Intensive Care Unit
ICDSC
Intensive Care Delirium Screening Checklist
HD
Hemodialysis
MoCA
Montreal Cognitive Assessment

Weeks to months: a structured, function-anchored workup

For change over weeks to months, the 2025 guidance from the Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT) network (expert consensus, separate from KDIGO graded recommendations) supports a structured, function-anchored assessment rather than screening by a single score.

Progressive difficulty (weeks to months)
1
Trajectory and function. Establish baseline and tempo. Ask about instrumental activities of daily living (IADLs): managing medicines, money, meals, transport, and appointments. Obtain collateral history from someone who knows the patient, with consent. Ask about falls and driving.
2
Reversible and contributing factors. Medication reconciliation with anticholinergic and sedative burden and renal dosing; sleep apnea symptoms; depression and anxiety; hearing and vision; alcohol and substance use; stroke history; dialysis pattern and intradialytic symptoms.
3
Targeted tests. Complete blood count including hemoglobin (Hb), electrolytes including sodium and calcium, glucose, kidney function, and, as indicated, thyroid-stimulating hormone (TSH) and vitamin B12. Direct imaging to the presentation rather than ordering it reflexively.
4
A brief cognitive screen when concern or functional change exists, using a validated version in the patient's language and checking the instrument's current terms of use. The Montreal Cognitive Assessment (MoCA) is more sensitive to executive dysfunction than the Mini-Mental State Examination (MMSE). Do not import a single universal cutoff across languages, education levels, or settings, and do not invent a universal re-screening interval.
5
Escalate persistent, atypical, rapidly progressive, or function-limiting problems to neurology, geriatrics, or psychiatry. A screening score alone cannot establish or exclude decision-making capacity.

Timing relative to dialysis matters more than most protocols acknowledge. Cognition fluctuates across the dialysis cycle, and intradialytic testing captures the hemodynamic trough. For serial assessment, test at a consistent, clinically stable time, ideally on a non-dialysis day or before treatment, and never treat a score obtained during acute illness or intradialytic symptoms as a comparable baseline. Practice effects inflate repeat scores, so a stable score on retesting may still conceal decline.

Schematic weekly timeline of hemodialysis on Monday, Wednesday, and Friday with a cognitive performance curve that dips during sessions; preferred testing windows are marked on a non-dialysis day and just before a session, and the intradialytic trough is marked to avoid.

Schematic only. Cognition fluctuates across the dialysis cycle; for serial testing, keep the timing, instrument version, and language the same, ideally on a non-dialysis day or before treatment.

Longitudinal data are sobering but selected. In a November 2026 longitudinal HD cohort, 247 patients were enrolled and 90 were retested after two years; MoCA fell by a mean 1.8 points, and 37 of 90 (41%) met the authors' definition of decline (a fall of more than 2 points), with steeper decline in men in adjusted analyses. With substantial attrition, this is not a general progression rate, a validated individual threshold, or a basis for a sex-specific risk score.

The brain during hemodialysis

Hemodialysis compresses about two to three days of fluid and solute removal into a few hours. Plasma refilling lags behind UF, intravascular volume falls, and the circulation defends BP through vasoconstriction and heart rate. In patients with impaired autoregulation, cerebral perfusion can fall even while brachial systolic BP (SBP) stays in an acceptable range.

Three findings frame practice. First, near-infrared spectroscopy detected a relative cerebral desaturation of more than 15% in 23.5% of 635 sessions in 58 prevalent patients; only 31.9% of these events were symptomatic, BP predicted them poorly, and the individual lower limit of autoregulation varied widely (mean arterial pressure 74.1 ± 17.6 mm Hg). Second, middle cerebral artery flow velocity declined during dialysis in proportion to UF volume, and the fall tracked intradialytic decline in global and executive function and, over 12 months, progression of white matter hyperintensities. Third, in a cohort of 118,394 maintenance HD patients, a mean ultrafiltration rate (UFR) >13 versus ≤13 mL/kg/h was associated with higher all-cause mortality (adjusted HR 1.31, 1.28–1.34). None of these establishes a cerebral-perfusion threshold, and the UFR data are mortality associations, not cognitive outcomes.

Physiology figure: three cerebral autoregulation curves show that the same mean arterial pressure during dialysis can sit on the plateau for one patient but on the falling limb for another with long-standing hypertension; a second panel shows brachial blood pressure changing little while cerebral oxygenation dips, with a note that desaturation occurred in 23.5 percent of 635 sessions and blood pressure predicted it poorly.

The lower limit of cerebral autoregulation varies between patients, so the same intradialytic blood pressure can protect one brain and underperfuse another. In a pilot study, blood pressure poorly predicted cerebral desaturation (MacEwen et al., 2017).

MAP
Mean arterial pressure
BP
Blood pressure

The KDIGO Controversies Conference on BP and volume management in dialysis (2020, consensus) emphasizes individualizing the prescription by integrating comorbidity, intradialytic hemodynamic patterns, and patient preference within a narrow therapeutic window. Practically:

LeverRationaleCaveat
Limit interdialytic weight gainSodium restriction reduces thirst and the volume to be removedDietary counseling must not compromise nutrition
Extend time or add a sessionRemoves the same volume at a lower UFRCost, chair availability, and Philippine Health Insurance Corporation (PhilHealth) session limits
Reassess target weightRecurrent symptoms may mean the target is set too lowVolume overload carries its own cardiovascular and cognitive risk
Review antihypertensive timingPre-dialysis doses can deepen intradialytic hypotensionInterdialytic hypertension must still be controlled
Document symptom timingLinks cognitive complaints to the hemodynamic profileSymptoms are not a validated ischemia detector

What has not worked for cognition. The Frequent Hemodialysis Network (FHN) trials found no benefit of six versus three sessions per week on executive function (Trail-Making Test B) or global cognition at 12 months. The cooler-dialysate feasibility trial (ECHECKED) (35 °C vs 36.5 °C) randomized 43, completed 27, and found no between-group difference in MoCA change. The cluster trial of center-wide personalized cooler dialysate (MyTEMP) showed no reduction in its cardiovascular composite and did not assess cognition. Review recurrent instability for the usual clinical reasons rather than prescribing a blanket "neuroprotective" protocol.

🚑

No form replaces the emergency pathway

A person who becomes acutely confused, aphasic, or weak during dialysis needs the stroke and emergency pathway, not a UFR calculation. The session review tool is for retrospective review of stable outpatients with recurrent symptoms.

Drug accumulation: the most reversible contributor

Medication review is the highest-yield intervention available, because drug-induced cognitive impairment is common, often reversible, and frequently missed in CKD. Work through each drug: indication, renal handling, CNS activity, dose relative to current kidney function, stating eGFR or creatinine clearance (CrCl) and the modality, and whether a safer alternative exists.

ClassExamplesKidney-relevant concern
First-generation antihistaminesDiphenhydramine; chlorphenamine, common in Philippine over-the-counter (OTC) cold and allergy combinationsStrong anticholinergic effect; delirium in older adults
Other anticholinergicsOxybutynin, tricyclic antidepressants, hyoscineCumulative anticholinergic burden
Muscle relaxantsBaclofenRenally cleared; encephalopathy hospitalization rises as eGFR falls (observational)
GabapentinoidsGabapentin, pregabalinRenally cleared; require dose reduction; sedation, dizziness, falls
OpioidsMorphine, codeine, tramadolActive metabolites accumulate; tramadol also lowers seizure threshold
Sedative-hypnoticsBenzodiazepines, zolpidemPsychomotor slowing, falls, delirium
Antimicrobials and antiviralsCefepime, acyclovir, valacyclovirNeurotoxicity with excess exposure in reduced clearance
OthersMetoclopramide, lithiumExtrapyramidal effects; narrow therapeutic index
Clinician reference card listing eight drug groups that can impair cognition in chronic kidney disease, with examples and concerns, and a footer advising review with the prescriber or pharmacist, stating eGFR or creatinine clearance and modality, and avoiding abrupt withdrawal.

Drug accumulation is the most reversible contributor. Review each CNS-active drug against current kidney function and modality; do not stop baclofen, benzodiazepines, or gabapentinoids abruptly.

CKD
Chronic kidney disease
eGFR
Estimated glomerular filtration rate
CrCl
Creatinine clearance
CNS
Central nervous system

Flag each for review with the clinician or pharmacist rather than assigning additive "burden points" or stopping automatically; abrupt withdrawal of baclofen, benzodiazepines, or gabapentinoids carries its own risk. Any drug-specific dosing tool should use a versioned, jurisdiction-specific label, state the renal metric explicitly, and handle AKI separately.

Copy-ready medication and cognition review note:

COGNITION — MEDICATION & CONTRIBUTOR REVIEW Tempo: acute/fluctuating (delirium pathway) | weeks–months | unclear Kidney function: eGFR ___ / CrCl ___ | modality: none / HD / PD / transplant Recent starts or dose changes (date): ___ Anticholinergics incl. OTC antihistamines: ___ Sedatives / hypnotics: ___ Opioids: ___ Baclofen ___ Gabapentin / pregabalin ___ Other renally cleared CNS-active: ___ Action: review with prescriber / pharmacist (no automatic stop) Contributors checked: Hb ___ Na ___ Ca ___ glucose ___ TSH ___ B12 ___ Sleep apnea screen ___ Depression screen ___ Hearing/vision ___ HD only: symptom timing pre/intra/post ___ | UFR ___ mL/kg/h | SBP nadir ___ Cognitive screen: instrument/version/language ___ score ___ timing vs HD ___ Collateral obtained (consent): Y / N IADL concerns: ___ Follow-up owner: ___ Next review: ___

What we can do today

No intervention has definitive randomized evidence for preventing or reversing CKD-associated cognitive decline. The rational strategy is to treat each contributor on its own indication and to protect the shared vascular bed.

StrategyEvidence and gradeHow to apply it
Blood pressure (nondialysis CKD)KDIGO 2021 suggests a target systolic BP <120 mm Hg, when tolerated, using standardized office measurement (2B). In the Systolic Blood Pressure Intervention Trial (SPRINT) extended follow-up (median 7 years), intensive control reduced the composite of mild cognitive impairment (MCI) or probable dementia (HR 0.89, 0.79–0.99) and MCI (0.87, 0.76–1.00); probable dementia alone was inconclusive (0.86, 0.72–1.02).SPRINT excluded diabetes and prior stroke and was not a dialysis trial; do not transfer the target to dialysis or to unstandardized readings. Individualize in frail older adults and those with orthostatic symptoms.
AnemiaKDIGO 2026 recommends targeting hemoglobin below 11.5 g/dL in adults treated with erythropoiesis-stimulating agents (ESAs) (Recommendation 3.3.1, 1D). Low hemoglobin is a cognitive-impairment correlate in HD.Treat anemia for symptoms and transfusion avoidance; do not intensify ESA or iron to improve a cognitive score.
Diabetes and cardiorenal therapySodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have proven kidney and cardiovascular indications (e.g., FLOW for semaglutide). A Korean cohort associated SGLT2 inhibitor use with lower Alzheimer and vascular dementia incidence (observational). Oral semaglutide did not slow early Alzheimer disease in evoke or evoke+ (3,808 patients; CDR-SB differences −0.08 and 0.10).Use for their kidney and cardiovascular indications; do not prescribe for cognition. Avoid hypoglycemia, a direct cause of acute confusion.
Physical activity and rehabilitationModerate activity is associated with lower dementia risk in CKD; exercise improves physical function.Individualized activity, intradialytic exercise where available; see the Interventions Made to Preserve Cognitive Function Trial (IMPCT) below.
Hearing, sleep, mood, social engagementAssociated with dementia risk in CKD cohorts (observational).Treat on their own merits: hearing assessment, sleep apnea evaluation, depression care, and social prescribing.
🧭

A trial of geriatric assessment that did not move the needle

The 2026 cluster-randomized geriatric assessment trial (GOAL) (15 Australian centers, 240 frail adults aged 65 or older with eGFR ≤59) found that a single outpatient comprehensive geriatric assessment did not improve goal attainment at three months (Goal Attainment Scaling 45.2 vs 43.7) or secondary outcomes. The lesson is not that geriatric input is futile but that one-off assessments need integration into ongoing kidney care to change outcomes.

What the trials actually measured

InterventionDesign and populationWhat was measuredInterpretation
Intradialytic cognitive plus exercise training (IMPCT)2×2 factorial randomized controlled trial (RCT), 121 adults within 3 years of starting HDPrimary: 3-month executive function, neutral. Secondary: MoCA improved by 2.1 points (0.4–3.9) with combined training vs standard careShort-term secondary signal; durability and dementia prevention untested. The 2026 virtual-reality training protocol (VIRTUAL) is a feasibility study, not efficacy evidence.
High-volume hemodiafiltration (HDF) (CONVINCE)RCT, 1,360 adults eligible for ≥23 L convection, median 30 monthsPatient-Reported Outcomes Measurement Information System (PROMIS) cognitive function: raw within-arm change −0.95 (−2.23 to 0.34) with HDF vs −3.90 (−5.28 to −2.52) with high-flux HD; joint model favored HDFPatient-reported, not objective cognition or dementia. The within-arm intervals are not a between-arm effect. A 2026 prespecified subgroup analysis found broadly consistent effects without clinically meaningful heterogeneity.
Thiamin plus folic acidDouble-blind RCT, 215 HD patients with cognitive impairment, 96 weeks (2026)Alzheimer's Disease Assessment Scale–Cognitive (ADAS-Cog) improved with thiamin 90 mg plus folic acid 30 mg daily; homocysteine fell; adverse events lowerSingle trial with an unusually large effect and very high folate doses; needs independent replication before it changes practice.
Cooler dialysate (ECHECKED; MyTEMP)Feasibility RCT, 43 randomized, 27 completed; cluster RCT of center policyNo MoCA difference; MyTEMP cardiovascular composite neutral, cognition not assessedAbsence of benefit in an underpowered study is not proof of no effect.
More frequent HD (FHN)Two RCTs, 6 vs 3 sessions per weekNo benefit on executive or global cognitionFrequency alone is not a cognitive therapy.
Kidney transplantationLongitudinal cohort (101 pre-transplant) and a 2026 systematic review (22 reports)Episodic and verbal memory normalized; MMSE and Trail-Making did not change. Review: no consistent global improvement; low to very low certainty by domainSome domains recover; others persist. A screening score should not act as an automatic eligibility filter; support decision-making and adherence instead.
Gut-derived toxin strategiesOral carbon adsorbent (AST-120), probiotics, prebiotics, aryl hydrocarbon receptor antagonists (largely preclinical)Biomarker changesNo proven cognitive benefit in CKD; not for clinical use for cognition.
Evidence map of interventions for cognition in CKD against three outcome types: exercise plus cognitive training and thiamin plus folic acid show objective benefit signals, hemodiafiltration shows a patient-reported benefit, transplant is mixed, cooler dialysate, frequent hemodialysis, and semaglutide showed no benefit, and no intervention measured dementia prevention in CKD.

What each intervention has actually been tested against. Benefit signals so far are short-term, secondary, single-trial, or patient-reported; none has shown dementia prevention in CKD.

CKD
Chronic kidney disease
RCT
Randomized controlled trial
⚖️

Reading the emerging evidence honestly

The most consistent signal so far is a patient-reported one (CONVINCE) and a short-term secondary objective one (IMPCT). Neither is a dementia outcome. Future trials need objective cognitive and functional endpoints, prespecified timing relative to dialysis, representative multilingual cohorts, accounting for competing mortality and missing follow-up, and enough duration to separate practice effects from sustained change.

Why there is no dementia risk calculator here

A 2026 systematic review identified 17 models predicting cognitive impairment, mild cognitive impairment, or cognitive frailty in CKD, most developed in HD populations. Some reported external areas under the curve of 0.75–0.90, but every model was at high risk of bias, calibration was rarely reported, and transportability across languages, education levels, and regions is unknown. That is why this guide does not offer a dementia-probability calculator, and why prevalence figures, hazard ratios, MoCA changes, UFR, or eGFR and UACR categories should never be converted into an individual dementia risk.

Three scenarios

Case 1: sudden change during dialysis. A 68-year-old man with diabetes becomes confused with slurred speech in the third hour of HD. His BP is 112/64 mm Hg and the UFR is 9 mL/kg/h. Reasoning: sudden focal speech disturbance is a stroke until proven otherwise. Stop UF, alert the physician, check capillary glucose, and activate the stroke pathway. Neither the acceptable BP nor the modest UFR excludes cerebral ischemia or hemorrhage.

Case 2: slow drift in a nondialysis patient. A 74-year-old woman with CKD G4 and UACR 80 mg/mmol has started missing tablets and a clinic visit over six months. Her daughter reports she now asks the same questions repeatedly. She takes a chlorphenamine-containing cold tablet most nights to sleep and was started on gabapentin for neuropathic pain at a dose not adjusted to her eGFR. Hemoglobin is 9.2 g/dL and she snores loudly. Reasoning: several reversible contributors coexist. Stop the nightly antihistamine with a sleep plan, reduce gabapentin to a renal dose, evaluate and treat anemia, refer for sleep study, and repeat a validated screen in her language once these are addressed, at a stable time, with her daughter present. Simplify the regimen with a weekly pill organizer and teach-back.

Case 3: transplant evaluation. A 55-year-old man on HD scores below the usual MoCA threshold on an intradialytic screen. Reasoning: an intradialytic score is not a comparable baseline. Repeat on a non-dialysis day; evaluate contributors; assess functional capacity and support for medication adherence. A single screen should not decide transplant candidacy, and some memory domains may improve after transplantation.

Applying this locally

Language and literacy. Screening instruments validated in English do not automatically transfer to Tagalog, Cebuano, Kapampangan, or other Philippine languages, nor across education levels. Use a validated translation where one exists, interpret scores against appropriate norms, and do not publish or improvise machine-translated test items.

Over-the-counter exposure. Many widely sold cold, flu, and allergy combinations contain chlorphenamine, and diphenhydramine is common in sleep aids. Ask specifically, because patients rarely list them as "medicines".

Family-centered care. Filipino families often share medication management and decision-making. Involve the family with the patient's consent, use teach-back with both, and remember that a screening score does not define capacity.

Session limits and hemodynamics. When financial constraints shorten treatment time or reduce frequency, UFR rises. PhilHealth coverage for hemodialysis was expanded to 156 sessions per year in 2025; confirm current benefits with PhilHealth or your facility before counseling. Document recurrent intradialytic symptoms so that longer sessions can be justified.

How strong is each claim?

ClaimCertainty rungKey source
About 40% of adults with CKD screen positive for cognitive impairmentObservational (meta-analysis; high heterogeneity)Zhang et al., 2024
Lower eGFR and higher albuminuria are associated with incident dementiaObservational (large cohorts)UK Biobank 2023; ARIC 2020
HD causes more cognitive impairment than PDNot established (confounded observational data)2026 modality meta-analysis
Cerebral desaturation occurs frequently during HD and is poorly predicted by BPDirect physiologic measurement (pilot)MacEwen et al., 2017
Baclofen at higher doses is associated with encephalopathy in CKDObservational (population cohorts)Muanda et al., 2019; Chauvin et al., 2020
Intensive BP control reduces MCI or probable dementiaRandomized (secondary, non-CKD-specific population)SPRINT 2025
Combined cognitive and exercise training improves MoCA in HDRandomized, secondary endpoint, short termIMPCT 2025
HDF slows patient-reported cognitive declineRandomized, patient-reported secondary outcomeCONVINCE 2024
Thiamin plus folic acid improves cognition in HDSingle randomized trial; needs replicationRenal Failure 2026
Gut-toxin reduction improves cognitionMechanistic hypothesisJASN 2025 review
Any model can predict an individual's dementia risk in CKDNot supported (all models high risk of bias)Frontiers in Public Health 2026
Glossary & abbreviationsTalahulugan at mga daglatTalaan sa mga pulong ug daglatTalatinigan ampo reng daglat terms used in this guide

Abbreviations

4AT
4 'A's Test — a short bedside test for delirium (Alertness, AMT4, Attention, Acute change).4 'A's Test — maikling test sa tabi ng kama para sa delirium.4 'A's Test — mubo nga pagsulay sa kilid sa higdaanan para sa delirium.4 'A's Test — maikling test king siping ning ulunan para king delirium.
ACR / UACR
Urine albumin-to-creatinine ratio — measures protein (albumin) leaking into the urine.Urine albumin-to-creatinine ratio — sumusukat sa protinang tumatagas sa ihi.Urine albumin-to-creatinine ratio — mosukod sa protina nga motulo sa ihi.Urine albumin-to-creatinine ratio — susukatan ing protinang lalakwas king ini.
ADAS-Cog
Alzheimer's Disease Assessment Scale–Cognitive subscale — a research test of thinking; higher scores mean more impairment.
AhR
Aryl hydrocarbon receptor — a cell receptor activated by some gut-derived uremic toxins.
AKI
Acute kidney injury — a sudden fall in kidney function over hours to days.Acute kidney injury — biglaang paghina ng bato sa loob ng ilang oras o araw.Acute kidney injury — kalit nga paghuyang sa kidney sulod sa pipila ka oras o adlaw.Acute kidney injury — biglang pamaglambut ning batu king pilan a oras o aldo.
AMT4
Abbreviated Mental Test – 4 — age, date of birth, place, and current year (part of the 4AT).
ARIC
Atherosclerosis Risk in Communities — a long-running United States cohort study.
BBB
Blood–brain barrier — the tightly sealed vessel lining that protects the brain.Blood–brain barrier — ang mahigpit na lining ng ugat na nagpoprotekta sa utak.Blood–brain barrier — ang hugot nga lining sa ugat nga manalipod sa utok.Blood–brain barrier — ing mayigpit a lining ning ugat a protektan ing utak.
BP
Blood pressure.Presyon ng dugo.Presyon sa dugo.Presyon ning daya.
BUN
Blood urea nitrogen — a waste product measured in the blood.
CAM-ICU
Confusion Assessment Method for the Intensive Care Unit — a delirium tool for critical care.
CDR-SB
Clinical Dementia Rating–Sum of Boxes — a scale of dementia severity used in trials.
CI
Confidence interval — the range within which the true value probably lies.
CKD
Chronic kidney disease.Chronic kidney disease — pangmatagalang sakit sa bato.Chronic kidney disease — dugay nga sakit sa kidney.Chronic kidney disease — matagal a sakit king batu.
CNS
Central nervous system — the brain and spinal cord.
CONNECT
Cognitive Decline in Nephro-Neurology: European Cooperative Target — a European research network.
CONVINCE
A large randomized trial comparing high-volume hemodiafiltration with high-flux hemodialysis.
CrCl
Creatinine clearance — an older estimate of kidney function used in some drug labels.
ECHECKED
A feasibility trial of cooler dialysate and cognition in hemodialysis.
eGFR
Estimated glomerular filtration rate — the main measure of kidney function.Estimated glomerular filtration rate — pangunahing sukat ng gana ng bato.Estimated glomerular filtration rate — nag-unang sukod sa gana sa kidney.Estimated glomerular filtration rate — pangunahing sukat ning gana ning batu.
ESA
Erythropoiesis-stimulating agent — an injection that helps the body make red blood cells.
FHN
Frequent Hemodialysis Network — trials of six versus three sessions per week.
FLOW
A randomized trial of semaglutide in type 2 diabetes and CKD.
GLP-1
Glucagon-like peptide-1 — a gut hormone; GLP-1 receptor agonists include semaglutide.
GOAL
A cluster-randomized trial of comprehensive geriatric assessment in frail older adults with CKD.
GRADE
Grading of Recommendations Assessment, Development and Evaluation — a system for rating evidence certainty.
Hb
Hemoglobin — the oxygen-carrying protein in red blood cells.Hemoglobin — protina sa pulang selula na nagdadala ng oxygen.Hemoglobin — protina sa pulang selula nga nagdala og oxygen.Hemoglobin — protina king malutu a selula a darang oxygen.
HD
Hemodialysis.Hemodialysis — paglilinis ng dugo gamit ang makina.Hemodialysis — paglimpyo sa dugo gamit ang makina.Hemodialysis — pamaglinis ning daya gamit ing makina.
HDF
Hemodiafiltration — dialysis that adds convection to remove more large molecules.Hemodiafiltration — dialysis na nag-aalis ng mas maraming malalaking dumi.Hemodiafiltration — dialysis nga mokuha og mas daghang dagkong hugaw.Hemodiafiltration — dialysis a alisan ing mas dakal a maragul a dinat.
HR
Hazard ratio — how much more (or less) often an event happens in one group than another over time.
IADLs
Instrumental activities of daily living — managing medicines, money, meals, transport, and appointments.
ICDSC
Intensive Care Delirium Screening Checklist.
IMPCT
Interventions Made to Preserve Cognitive Function Trial — intradialytic exercise and brain training.
IS / PCS
Indoxyl sulfate and p-cresyl sulfate — protein-bound uremic toxins made partly by gut bacteria.
KDIGO
Kidney Disease: Improving Global Outcomes — the international kidney guideline organization.
MCA
Middle cerebral artery — a major artery supplying the brain.
MCI
Mild cognitive impairment — measurable thinking changes without loss of independence.
MMSE
Mini-Mental State Examination — a brief screening test of thinking.
MoCA
Montreal Cognitive Assessment — a brief screening test that includes executive function.Montreal Cognitive Assessment — maikling test sa pag-iisip.Montreal Cognitive Assessment — mubo nga pagsulay sa panghunahuna.Montreal Cognitive Assessment — maikling test king pamanisip.
MyTEMP
A cluster-randomized trial of personalized cooler dialysate.
NICE
National Institute for Health and Care Excellence (United Kingdom).
OTC
Over-the-counter — medicines sold without a prescription.Over-the-counter — gamot na nabibili nang walang reseta.Over-the-counter — tambal nga mapalit nga walay reseta.Over-the-counter — gamot a mabibili a ala reseta.
PD
Peritoneal dialysis — dialysis using the lining of the abdomen, usually at home.Peritoneal dialysis — dialysis gamit ang lining ng tiyan, karaniwang sa bahay.Peritoneal dialysis — dialysis gamit ang lining sa tiyan, kasagaran sa balay.Peritoneal dialysis — dialysis gamit ing lining ning atian, karaniwan king bale.
PROMIS
Patient-Reported Outcomes Measurement Information System — standardized questionnaires.
RCT
Randomized controlled trial.
rSO₂
Regional cerebral oxygen saturation, measured by near-infrared spectroscopy.
SBP
Systolic blood pressure — the top number.
SGLT2
Sodium–glucose cotransporter 2 — target of kidney-protective drugs such as dapagliflozin.
SPRINT
Systolic Blood Pressure Intervention Trial.
TSH
Thyroid-stimulating hormone — a thyroid blood test.
UF
Ultrafiltration — fluid removal during dialysis.Ultrafiltration — pag-alis ng tubig habang nagda-dialysis.Ultrafiltration — pagkuha sa tubig panahon sa dialysis.Ultrafiltration — pamaglako danum kabang magda-dialysis.
UFR
Ultrafiltration rate — fluid removed per kilogram of body weight per hour (mL/kg/h).
VIRTUAL
A feasibility trial protocol of virtual-reality cognitive training in hemodialysis.
WMH
White matter hyperintensities — bright spots on brain MRI that mark small-vessel injury.

Terms

Albuminuria
Protein (albumin) in the urine; a marker of kidney and blood-vessel damage.Protina (albumin) sa ihi; palatandaan ng pinsala sa bato at ugat.Protina (albumin) sa ihi; timaan sa kadaot sa kidney ug ugat.Protina (albumin) king ini; tanda ning pinsala king batu at ugat.
Anticholinergic
A drug effect that blocks the brain chemical acetylcholine; can cause confusion, dry mouth, and constipation.Epekto ng gamot na humaharang sa acetylcholine sa utak; maaaring magdulot ng kalituhan.Epekto sa tambal nga mobabag sa acetylcholine sa utok; makahatag og kalibog.Epektu ning gamot a arangan ing acetylcholine king utak; malyari yang magdulot kalituan.
Autoregulation
The ability of the brain and kidney to keep their blood flow steady despite changes in blood pressure.Kakayahan ng utak at bato na panatilihing matatag ang daloy ng dugo kahit nagbabago ang presyon.Abilidad sa utok ug kidney nga ipabilin nga lig-on ang agos sa dugo bisan mausab ang presyon.Kakayanan ning utak at batu a panatilian matibe ing dalan ning daya agyang mibayu ing presyon.
Cognition
All the ways the brain takes in, holds, and uses information: attention, memory, planning, language, and speed.Lahat ng paraan ng utak sa pagtanggap, paghawak, at paggamit ng impormasyon.Tanang paagi sa utok sa pagdawat, paghupot, ug paggamit sa impormasyon.Sablang paralan ning utak king pamanggap, pamaggawak, at pamamigamit impormasyun.
Delirium
A sudden, fluctuating disturbance of attention and awareness, usually caused by illness or medicines; a medical emergency.Biglaan at pabago-bagong gulo sa atensyon at kamalayan, kadalasang dahil sa sakit o gamot; emergency.Kalit ug pabalik-balik nga kagubot sa atensyon ug kahibalo, kasagaran tungod sa sakit o tambal; emergency.Biglang gulu king atensyon at kamalayan, maralas uli ning sakit o gamot; emergency.
Dementia
A lasting decline in thinking severe enough to interfere with independence.Pangmatagalang paghina ng pag-iisip na sapat na para makaapekto sa kalayaan.Dugay nga paghuyang sa panghunahuna nga igo aron maapektuhan ang kagawasan.Matagal a pamaglambut ning pamanisip a sapat bang apektuan ing kalayaan.
Dialysis disequilibrium syndrome
Brain swelling and confusion from rapid solute removal, mainly around the first dialysis sessions.
Executive function
Planning, organizing, switching between tasks, and controlling impulses.Pagpaplano, pag-oorganisa, paglipat-lipat ng gawain, at pagkontrol sa sarili.Pagplano, pag-organisar, pagbalhin-balhin sa buluhaton, ug pagkontrol sa kaugalingon.Pamagplanu, pamag-organisa, pamaglipat-lipat obra, at pamagkontrol king sarili.
Interdialytic weight gain
Weight gained between hemodialysis sessions, mostly fluid.Timbang na nadagdag sa pagitan ng hemodialysis, karamihan ay tubig.Timbang nga nadugang tali sa hemodialysis, kasagaran tubig.Timbang a midagdag king pagitan ning hemodialysis, kalupan danum.
Practice effect
Improvement on a repeated test from familiarity rather than true change.
Protein-bound uremic toxins
Waste products that cling to blood proteins and are removed poorly by standard dialysis.
Teach-back
Asking the patient to explain the plan in their own words to confirm understanding.Pagpapaliwanag ng pasyente sa plano sa sarili niyang salita.Pagpasabot sa pasyente sa plano sa iyang kaugalingong pulong.Pamagpaliwanag ning pasyente king planu king sariling amanu na.
Uremic encephalopathy
Brain dysfunction caused by advanced kidney failure; improves with dialysis.Problema sa utak dahil sa malalang kidney failure; bumubuti sa dialysis.Problema sa utok tungod sa grabe nga kidney failure; muayo sa dialysis.Problema king utak uli ning malalang kidney failure; mumayap king dialysis.
White matter
The brain's wiring that connects different regions; vulnerable to small-vessel disease.
ReferencesMga SanggunianMga TinubdanReng Reperensya 45 sources
  1. Zhang, J., Wu, L., Wang, P., Pan, Y., Dong, X., Jia, L., & Zhang, A. (2024). Prevalence of cognitive impairment and its predictors among chronic kidney disease patients: A systematic review and meta-analysis. PLOS ONE, 19(6), e0304762. https://doi.org/10.1371/journal.pone.0304762
  2. Malik, A., Mansour, H. R. K., Kundur, S. P., Hunjan, A., & Zaheer, R. (2025). Dialysis modality and cognitive outcomes in chronic kidney disease: A systematic review and meta-analysis. Clinical and Experimental Nephrology, 30(3), 408–423. https://doi.org/10.1007/s10157-025-02798-2
  3. Yeh, T. S., Clifton, L., Collister, J. A., Liu, X., Hunter, D. J., & Littlejohns, T. J. (2023). Kidney function, albuminuria, and their modification by genetic factors and risk of incident dementia in UK Biobank. Alzheimer's Research & Therapy, 15(1), 138. https://doi.org/10.1186/s13195-023-01248-z
  4. Scheppach, J. B., Coresh, J., Wu, A., Gottesman, R. F., Mosley, T. H., Knopman, D. S., Grams, M. E., Sharrett, A. R., & Koton, S. (2020). Albuminuria and estimated GFR as risk factors for dementia in midlife and older age: Findings from the ARIC study. American Journal of Kidney Diseases, 76(6), 775–783. https://doi.org/10.1053/j.ajkd.2020.03.015
  5. Kelly, D. M., Kelleher, E. M., & Rothwell, P. M. (2026). Acute kidney injury and risk of adverse neurocognitive outcomes: A systematic review and meta-analysis. Neurology, 106(11), e218031. https://doi.org/10.1212/WNL.0000000000218031
  6. Bui, H. T., Apriliyasari, R. W., Bui, Q. H. Q., & Tsai, P. S. (2026). Association between frailty and cognitive impairment in chronic kidney disease: A systematic review and meta-analysis. Journal of Nursing Scholarship, 58(4), e70110. https://doi.org/10.1111/jnu.70110
  7. Huang, L., Pei, L., Li, C., Cili, N., Yang, H., Gesang, D., Song, H., Fu, P., & Zeng, X. (2026). Disease susceptibility and risk of dementia in patients with chronic kidney disease: A prospective cohort study based on UK Biobank. BMC Neurology, 26(1). https://doi.org/10.1186/s12883-026-05212-w
  8. Liu, J., Wan, J. F., Chen, J., Zhang, W. W., Peng, C. X., He, Y. N., & Chen, K. H. (2026). Risk factors for cognitive impairment in patients undergoing hemodialysis: An umbrella review and meta-analysis. Renal Failure, 48(1), 2741985. https://doi.org/10.1080/0886022X.2026.2741985
  9. Bolignano, D., Simeoni, M., Hafez, G., Pepin, M., Gallo, A., Altieri, M., Liabeuf, S., Giannakou, K., De, A., & Capasso, G. (2024). Cognitive impairment in CKD patients: A guidance document by the CONNECT network. Clinical Kidney Journal, 18(2), sfae294. https://doi.org/10.1093/ckj/sfae294
  10. Andrews, T. D., Day, G. S., Irani, S. R., Kanekiyo, T., & Hickson, L. J. (2025). Uremic toxins, CKD, and cognitive dysfunction. Journal of the American Society of Nephrology, 36(6), 1208–1226. https://doi.org/10.1681/ASN.0000000675
  11. Kurella Tamura, M., Chertow, G. M., Depner, T. A., Nissenson, A. R., Schiller, B., Mehta, R. L., Liu, S., & Sirich, T. L. (2016). Metabolic profiling of impaired cognitive function in patients receiving dialysis. Journal of the American Society of Nephrology, 27(12), 3780–3787. https://doi.org/10.1681/ASN.2016010039
  12. MacEwen, C., Sutherland, S., Daly, J., Pugh, C., & Tarassenko, L. (2017). Relationship between hypotension and cerebral ischemia during hemodialysis. Journal of the American Society of Nephrology, 28(8), 2511–2520. https://doi.org/10.1681/ASN.2016060704
  13. Findlay, M. D., Dawson, J., Dickie, D. A., Forbes, K. P., McGlynn, D., Quinn, T., & Mark, P. B. (2018). Investigating the relationship between cerebral blood flow and cognitive function in hemodialysis patients. Journal of the American Society of Nephrology, 30(1), 147–158. https://doi.org/10.1681/ASN.2018050462
  14. Lin, Y., Zhao, Z., Zhu, N., Garcia Ptacek, S., Carrero, J. J., Bruchfeld, A., Eriksdotter, M., Mielke, M. M., Brusselaers, N., & Xu, H. (2026). Kidney function and blood and cerebrospinal fluid biomarkers in Alzheimer's disease and related dementias: Systematic review and meta-analysis. Journal of the American Society of Nephrology, 37(7), 1507–1523. https://doi.org/10.1681/ASN.0000001007
  15. Yun, J., Lee, J., Shin, D., Lee, E. H., Kim, J. P., Ham, H., Gu, Y., Chun, M. Y., Kang, S. H., Kim, H. J., Na, D. L., Kim, K. W., Kim, S. E., Kim, Y., Kim, J., Jung, N. Y., Kim, Y. J., Cho, S. H., Lee, J. S., ... Jang, H. (2026). Plasma phosphorylated tau 217 cutoffs for amyloid pathology and kidney function, body mass index, and anemia. JAMA Neurology, 83(3), 269–279. https://doi.org/10.1001/jamaneurol.2025.5530
  16. Sheets, K. M., Curran, J. M., Mielke, M. M., Zeng, X., Karikari, T. K., Sutphen, C. L., Register, T. C., & Murray, A. M. (2026). Chronic kidney disease and blood-based biomarkers of Alzheimer's disease: The Brain in Kidney Disease study. Alzheimer's & Dementia, 22(10), e71940. https://doi.org/10.1002/alz.71940
  17. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
  18. National Institute for Health and Care Excellence (NICE). (2023). Delirium: Prevention, diagnosis and management in hospital and long-term care (Clinical Guideline CG103; updated January 2023). https://www.nice.org.uk/guidance/cg103
  19. Bellelli, G., Morandi, A., Davis, D. H., Mazzola, P., Turco, R., Gentile, S., Ryan, T., Cash, H., Guerini, F., Torpilliesi, T., Del Santo, F., Trabucchi, M., Annoni, G., & MacLullich, A. M. (2014). Validation of the 4AT, a new instrument for rapid delirium screening: A study in 234 hospitalised older people. Age and Ageing, 43(4), 496–502. https://doi.org/10.1093/ageing/afu021
  20. Tieges, Z., Maclullich, A. M. J., Anand, A., Brookes, C., Cassarino, M., O'Connor, M., Ryan, D., Saller, T., Arora, R. C., Chang, Y., Agarwal, K., Taffet, G., Quinn, T., Shenkin, S. D., & Galvin, R. (2021). Diagnostic accuracy of the 4AT for delirium detection in older adults: Systematic review and meta-analysis. Age and Ageing, 50(3), 733–743. https://doi.org/10.1093/ageing/afaa224
  21. MacLullich, A., Ryan, T., & Cash, H. (2014). The 4AT: Rapid clinical test for delirium (Licensed under CC BY 4.0). https://www.the4at.com
  22. Muanda, F. T., Weir, M. A., Bathini, L., Blake, P. G., Chauvin, K., Dixon, S. N., McArthur, E., Sontrop, J. M., Moist, L., & Garg, A. X. (2019). Association of baclofen with encephalopathy in patients with chronic kidney disease. JAMA, 322(20), 1987–1995. https://doi.org/10.1001/jama.2019.17725
  23. Chauvin, K. J., Blake, P. G., Garg, A. X., Weir, M. A., Bathini, L., Dixon, S. N., McArthur, E., Sontrop, J. M., Moist, L., Kim, R. B., & Muanda, F. T. (2020). Baclofen has a risk of encephalopathy in older adults receiving dialysis. Kidney International, 98(4), 979–988. https://doi.org/10.1016/j.kint.2020.04.047
  24. Schäfer, H., Braunisch, M., Günthner, R., Küchle, C., Basta-Wunderle, M., Haller, B., Heemann, U., Schmaderer, C., & Angermann, S. (2026). Longitudinal assessment of cognitive decline in hemodialysis patients: Unveiling sex disparities. Clinical Kidney Journal, 19(11), sfag340. https://doi.org/10.1093/ckj/sfag340
  25. Assimon, M. M., Wenger, J. B., Wang, L., & Flythe, J. E. (2016). Ultrafiltration rate and mortality in maintenance hemodialysis patients. American Journal of Kidney Diseases, 68(6), 911–922. https://doi.org/10.1053/j.ajkd.2016.06.020
  26. Flythe, J. E., Chang, T. I., Gallagher, M. P., Lindley, E., Madero, M., Sarafidis, P. A., Unruh, M. L., Wang, A. Y., Weiner, D. E., Cheung, M., Jadoul, M., Winkelmayer, W. C., & Polkinghorne, K. R. (2020). Blood pressure and volume management in dialysis: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 97(5), 861–876. https://doi.org/10.1016/j.kint.2020.01.046
  27. Kurella Tamura, M., Unruh, M. L., Nissenson, A. R., Larive, B., Eggers, P. W., Gassman, J., Mehta, R. L., Kliger, A. S., & Stokes, J. B. (2012). Effect of more frequent hemodialysis on cognitive function in the Frequent Hemodialysis Network trials. American Journal of Kidney Diseases, 61(2), 228–237. https://doi.org/10.1053/j.ajkd.2012.09.009
  28. Dasgupta, I., Odudu, A., Baharani, J., Fergusson, N., Griffiths, H., Harrison, J., Hameed, A., Maruff, P., Ryan, L., Thomas, N., Woodhall, G., & Tadros, G. (2024). Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results. BMC Nephrology, 25(1), 466. https://doi.org/10.1186/s12882-024-03883-6
  29. MyTEMP Writing Committee. (2022). Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): A pragmatic, cluster-randomised trial. The Lancet, 400(10364), 1693–1703. https://doi.org/10.1016/S0140-6736(22)01805-0
  30. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. (2021). KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney International, 99(3S), S1–S87. https://doi.org/10.1016/j.kint.2020.11.003
  31. Reboussin, D. M., Gaussoin, S. A., Pajewski, N. M., Jaeger, B. C., Sachs, B., Rapp, S. R., Supiano, M. A., Cleveland, M. L., Hunter, V., Demons, J. L., Ogrocki, P. K., Lerner, A. J., Chelune, G. J., Wadley, V. G., Scales, M. L., Woolard, N. F., Perdue, L. H., Callahan, K. E., & Williamson, J. D. (2025). Long-term effect of intensive vs standard blood pressure control on mild cognitive impairment and probable dementia in SPRINT. Neurology, 104(3), e213334. https://doi.org/10.1212/WNL.0000000000213334
  32. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2026). KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney International, 109(1S), S1–S99. https://doi.org/10.1016/j.kint.2025.06.006
  33. Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. The New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
  34. Kim, H. K., Biessels, G. J., Yu, M. H., Hong, N., Lee, Y. H., Lee, B. W., Kang, E. S., Cha, B. S., Lee, E. J., & Lee, M. (2024). SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes. Neurology, 103(8), e209805. https://doi.org/10.1212/WNL.0000000000209805
  35. Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., & Feldman, H. H. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): Two phase 3, randomised, placebo-controlled trials. The Lancet, 407(10544), 2167–2179. https://doi.org/10.1016/S0140-6736(26)00459-9
  36. Logan, B., Viecelli, A. K., Johnson, D. W., Comans, T., Gordon, E. H., Gray, L. C., Hawley, C. M., Hickey, L. E., Janda, M., Jaure, A., Jose, M. D., Kiriwandeniya, C., Matsuyama, M., Mihala, G., Nguyen, K. H., Pascoe, E. M., Paul-Brent, P. A., Pole, J. D., Polkinghorne, K. R., ... Hubbard, R. E. (2026). A cluster randomized controlled trial (GOAL trial) evaluated a comprehensive geriatric assessment for frail older people with chronic kidney disease. Kidney International, 110(4), 1000–1012. https://doi.org/10.1016/j.kint.2026.05.015
  37. Ghildayal, N., Liu, Y., Hong, J., Li, Y., Chen, X., Fernández, M. G., Carlson, M. C., Fine, D. M., Appel, L. J., Diener-West, M., Charytan, D. M., Mathur, A., Segev, D. L., & McAdams-DeMarco, M. (2025). Intradialytic cognitive and aerobic exercise training to preserve cognitive function: IMPCT, a multi-dialysis center 2 × 2 factorial block-randomized controlled trial. American Journal of Nephrology, 57(1), 1–13. https://doi.org/10.1159/000546296
  38. Viggiano, D., Pellegrino, G., Natale, P., Buonincontri, V., Gigliotti, G., Genualdo, R., Nappi, F., De Nicola, L., Iodice, C., Iannuzzi, M., Iulianiello, P., Auricchio, M. R., Zamboli, P., Montinaro, V., & Strippoli, G. (2026). Virtual reality training for cognitive impairment in adults treated with haemodialysis (VIRTUAL): Protocol for a feasibility randomised controlled trial. BMJ Open, 16(6), e120700. https://doi.org/10.1136/bmjopen-2026-120700
  39. Rose, M., Fischer, F. H., Liegl, G., Strippoli, G. F. M., Hockham, C., Vernooij, R. W. M., Barth, C., Canaud, B., Covic, A., Cromm, K., Cucui, A. M., Davenport, A., Fischer, K. I., Hegbrant, J., Jaha, H., Schappert, A., Török, M., Woodward, M., Bots, M. L., & Blankestijn, P. J. (2024). The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration. Kidney International, 106(5), 961–971. https://doi.org/10.1016/j.kint.2024.07.014
  40. Cromm, K., Fischer, F., Pellegrino, G., Vernooij, R. W. M., Riazy, L., Barth, C., Blankestijn, P. J., Bots, M. L., Canaud, B., Davenport, A., Hegbrant, J., Woodward, M., Rose, M., & Strippoli, G. F. M. (2026). Patient-reported outcomes with high-volume hemodiafiltration versus high-flux hemodialysis across clinical subgroups: Results from the CONVINCE trial. Clinical Journal of the American Society of Nephrology. Advance online publication. https://doi.org/10.2215/CJN.0000001253
  41. Xie, K., Jiang, Y., Chen, T., Liu, S., Fang, Y., Chen, F., Shen, J., Zeng, X., Li, P., Qiu, T., Wang, J., Yu, L., Zang, X., Wang, N., Yuan, J., Pang, H., Zhang, W., Ni, Z., Gu, L., ... Lu, R. (2026). A prospective, randomized, double-blind, placebo-controlled, multicenter study of thiamin plus folic acid in the treatment of cognitive impairment in patients undergoing maintenance hemodialysis. Renal Failure, 48(1), 2658981. https://doi.org/10.1080/0886022X.2026.2658981
  42. Gupta, A., Mahnken, J. D., Bernal, J., Sharma, P., Lepping, R. J., Montgomery, R. N., Johnson, D. K., Parks, A., Burns, J. M., Drew, D. A., Sarnak, M. J., & Brooks, W. M. (2024). Changes in cognitive function after kidney transplantation: A longitudinal cohort study. American Journal of Kidney Diseases, 84(1), 28–37.e1. https://doi.org/10.1053/j.ajkd.2023.12.022
  43. Tang, Y., Xu, J., & Chen, J. (2026). Cognitive function after kidney transplantation: Longitudinal trajectories, associated factors, and clinical outcomes—a systematic review. International Urology and Nephrology. Advance online publication. https://doi.org/10.1007/s11255-026-05352-5
  44. Dong, L., Chen, Y., Lin, X., Shi, J., Liu, H., & Zhong, Y. (2026). Risk prediction models for cognitive impairment in patients with chronic kidney disease: A systematic review. Frontiers in Public Health, 14, 1851336. https://doi.org/10.3389/fpubh.2026.1851336
  45. Philippine Health Insurance Corporation (PHIC). (2025, March 27). PhilHealth's expanded benefits bring financial relief to dialysis patients [News release]. https://www.philhealth.gov.ph/news/up/article/2025/news_67e9e793775ed.php
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save